<SEC-DOCUMENT>0001213900-25-029372.txt : 20250501
<SEC-HEADER>0001213900-25-029372.hdr.sgml : 20250501
<ACCEPTANCE-DATETIME>20250407151234
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001213900-25-029372
CONFORMED SUBMISSION TYPE:	DRS
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20250407
<PUBLIC-REL-DATE>20250501
DATE AS OF CHANGE:		20250407

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Pasithea Therapeutics Corp.
		CENTRAL INDEX KEY:			0001841330
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				851591963
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DRS
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	377-07863
		FILM NUMBER:		25817850

	BUSINESS ADDRESS:	
		STREET 1:		1111 LINCOLN ROAD, SUITE 500
		CITY:			MIAMI BEACH
		STATE:			FL
		ZIP:			33139
		BUSINESS PHONE:		(702) 514-4174

	MAIL ADDRESS:	
		STREET 1:		1111 LINCOLN ROAD, SUITE 500
		CITY:			MIAMI BEACH
		STATE:			FL
		ZIP:			33139
</SEC-HEADER>
<DOCUMENT>
<TYPE>DRS
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>As confidentially submitted to the Securities
and Exchange Commission on [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;], 2025. This draft registration statement has not been filed publicly with
the Securities and Exchange Commission and all information herein remains strictly confidential.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.15pt; text-align: right"><B>Registration No. 333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM S</B>-<B>1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REGISTRATION STATEMENT UNDER THE SECURITIES
ACT OF 1933</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PASITHEA
    THERAPEUTICS CORP.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">(Exact name of registrant as specified in its charter)</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 32%"><B>Delaware</B></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 32%"><B>001-40804</B></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 32%"><B>85-1591963</B></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or other jurisdiction of<BR>
 incorporation
    or organization)</P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Primary Standard Industrial</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Classification Code Number)</P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(I.R.S. Employer</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Identification No.)</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>1111 Lincoln Road, Suite 500</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Miami Beach, Florida 33139</B></P>

<P STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Telephone:
(786) 977-3380</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address, including zip code, and telephone number,
including area code, of registrant&rsquo;s principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Tiago Reis Marques</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Chief Executive Officer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>1111 Lincoln Road, Suite 500</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Miami Beach, Florida 33139</B></P>

<P STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(786) 977-3380</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Name, address, including zip code, and telephone
number, including area code, of agent for service)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Please send copies of all communications to:
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>James O&rsquo;Grady, Esq.</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Lowenstein Sandler LLP</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>1251 Avenue of the Americas</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>New York, New York 10020</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Telephone: (212) 262-6700</B></P></TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Approximate date of commencement of proposed
sale to the public:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05pt; text-align: center"><B>As soon as practicable after the
effective date of this registration statement.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If any of the securities being registered on this
Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box:
<FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this Form is filed to register additional securities
for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration
statement number of the earlier effective registration statement for the same offering: <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this Form is a post-effective amendment filed
pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of
the earlier effective registration statement for the same offering: <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this Form is a post-effective amendment filed
pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of
the earlier effective registration statement for the same offering: <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company.
See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo; &ldquo;smaller reporting company,&rdquo;
and &ldquo;emerging growth company&rdquo; in Rule 12b-2 of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Large accelerated filer</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Accelerated filer</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Non-accelerated filer</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Smaller reporting company</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Emerging growth company</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The Registrant hereby amends this Registration
Statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment that
specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities
Act of 1933 or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting
pursuant to said Section 8(a), may determine.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><B>PRELIMINARY&nbsp;PROSPECTUS
    </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><B>Subject
    to Completion </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><B>Dated:
    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2025</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><B>The
information contained in this preliminary prospectus is not complete and may be changed. These securities may not be sold until the registration
statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities
and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares of Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pre-Funded Warrants to Purchase up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shares
of Common Stock </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Common Warrants to Purchase up to  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares of
Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Shares of Common Stock underlying Pre-Funded
Warrants and Common Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are offering &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares
of common stock, together with warrants to purchase shares of common stock, each a Common Warrant, at an assumed combined public offering
price of $ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share and Common Warrant, which is equal to the closing price per share of our common stock
on The Nasdaq Capital Market (&ldquo;Nasdaq&rdquo;), on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2025 pursuant to this prospectus. The shares of
common stock and Common Warrants will be separately issued, but must be purchased together in this offering. Each share of common stock
is being sold together with one Common Warrant to purchase one share of common stock. Each Common Warrant will have an exercise price
of $ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share (representing 100% of the combined price at which a share of common stock and accompanying
Common Warrant are sold to the public in this offering), will expire &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;years from the date of issuance and
will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the Common
Warrants (&ldquo;Warrant Stockholder Approval&rdquo;); <U>provided</U>, <U>however</U>, if the Pricing Conditions (as defined below) are
met, the Common Warrants will be exercisable upon issuance (the &ldquo;Initial Exercise Date&rdquo;). As used herein, &ldquo;Pricing Conditions&rdquo;
means that the combined offering price per share and accompanying Common Warrant is such that Warrant Stockholder Approval is not required
under the rules of The Nasdaq Stock Market LLC (&ldquo;Nasdaq&rdquo;) because either (i) the offering is an at-the-market offering under
Nasdaq rules and such price equals or exceeds the sum of (a) the applicable &ldquo;Minimum Price&rdquo; per share under Nasdaq Rule 5635(d)
plus (b) $0.125 per whole share of common stock underlying each Common Warrant or (ii) the offering is a discounted offering where the
pricing and discount (including attributing a value of $0.125 per whole share underlying each Common Warrant) meet the pricing requirements
under Nasdaq&rsquo;s rules.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are also offering pre-funded warrants, or Pre-Funded
Warrants, to purchase up to an aggregate of  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock to those purchasers whose purchase of shares of common stock in this
offering would result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99%
(or, at the election of the purchaser, 9.99%) of our outstanding common stock following the consummation of this offering in lieu of the
shares of our common stock that would result in ownership in excess of 4.99% (or, at the election of the purchaser, 9.99%). Each Pre-Funded
Warrant will be exercisable for one share of common stock at an exercise price of $0.001 per share. Each Pre-Funded Warrant is being issued
together with the same Common Warrant described above being issued with each share common stock. The assumed combined public offering
price for each such Pre-Funded Warrant, together with the Common Warrant, is $  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, which is equal to the closing price of our common stock
on Nasdaq on  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2025, less the $0.001 per share exercise price of each such Pre-Funded Warrant. Each Pre-Funded Warrant will be exercisable
upon issuance and will expire when exercised in full. The Pre-Funded Warrants and Common Warrants are immediately separable and will be
issued separately in this offering, but must be purchased together in this offering. For each Pre-Funded Warrant we sell, the number of
shares of common stock we are offering will be decreased on a one-for-one basis. This offering also relates to the shares of common stock
issuable upon the exercise of the Pre-Funded Warrants and the Common Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This offering will terminate on  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, unless we decide
to terminate the offering (which we may do at any time in our discretion) prior to that date. We will have one closing for all the securities
purchased in this offering. The combined public offering price per share (or Pre-Funded Warrant) and Common Warrant will be fixed for
the duration of this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have engaged  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, or the placement agent, to act
as our exclusive placement agent in connection with this offering. The placement agent has agreed to use its reasonable best efforts to
arrange for the sale of the securities offered by this prospectus. The placement agent is not purchasing or selling any of the securities
we are offering and the placement agent is not required to arrange the purchase or sale of any specific number or dollar amount of securities.
We have agreed to pay to the placement agent the placement agent fees set forth in the table below, which assumes that we sell all of
the securities offered by this prospectus. There is no arrangement for funds to be received in escrow, trust or similar arrangement. There
is no minimum offering requirement. We will bear all costs associated with the offering. See &ldquo;Plan of Distribution&rdquo; on page
<FONT>17</FONT> of this prospectus for more information regarding these arrangements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our common stock and certain of our outstanding warrants are currently listed on Nasdaq under the symbol &ldquo;KTTA&rdquo; and &ldquo;KTTAW,&rdquo;
respectively. On March  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2025, the closing price of our common stock on Nasdaq was $  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share. All share, Common Warrant, and Pre-Funded
Warrant numbers are based on an assumed combined public offering price of $  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share and accompanying Common Warrant and $  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per Pre-Funded
Warrant and the accompanying Common Warrant. There is no established public trading market for the Pre-Funded Warrants or Common Warrants
that are part of this offering, and we do not expect a market to develop. We do not intend to apply for listing of the Pre-Funded Warrants
or Common Warrants on any securities exchange or other nationally recognized trading system. Without an active trading market, the liquidity
of the Pre-Funded Warrants and Common Warrants will be limited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain information in this prospectus is based
on an assumed combined public offering price of $  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share and accompanying Common Warrant, the last reported sale price of our common
stock on Nasdaq on  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2025 (or assumed combined public offering price of $ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per Pre-Funded Warrant and accompanying Common Warrant).&nbsp;The
actual combined public offering price per share and Common Warrant and the actual combined public offering price per Pre-Funded Warrant
and Common Warrant, as the case may be, will be determined between us, the placement agent and investors in this offering based on market
conditions at the time of pricing and may be at a discount to the current market price of our common stock. Therefore, the recent market
price used throughout this prospectus may not be indicative of the final offering price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You should read this prospectus, together with
additional information described under the headings &ldquo;Information Incorporated by Reference&rdquo; and &ldquo;Where You Can Find
More Information,&rdquo; carefully before you invest in any of our securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are an &ldquo;emerging growth
company&rdquo; as that term is used in the Jumpstart Our Business Startups Act of 2012 and a &ldquo;smaller reporting
company&rdquo;, and as such, we have elected to take advantage of certain reduced public company reporting requirements for this
prospectus and future filings. Investing in our securities involves a high degree of risk. See &ldquo;Risk Factors&rdquo; beginning
on page 6 of this prospectus for a discussion of information that should be considered in connection with an investment in our
securities. See &ldquo;Prospectus Summary &mdash; Implications of Being an Emerging Growth Company&rdquo; and &ldquo;Prospectus
Summary &mdash; Implications of Being a Smaller Reporting Company.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Investing in our securities involves a high
degree of risk. See the section titled &ldquo;Risk Factors&rdquo; beginning on page <FONT>6</FONT>
of this prospectus and in the documents incorporated by reference into this prospectus for a discussion of risks that should be considered
in connection with an investment in our securities. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">Per Share and Accompanying Common Warrant</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">Per Pre-Funded Warrant and Accompanying Common Warrant</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">Total</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Public offering price</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Placement Agent Fees (1)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Proceeds to us, before expenses (2)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="font: 10pt Times New Roman, Times, Serif; width: 25%"><DIV STYLE="font: 10pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid"></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in">(1)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">We have also agreed to reimburse the placement agent for certain of
its offering related expenses. In addition, we have agreed to issue the placement agent or its designees warrants to purchase a number
of shares of common stock equal to 7% of the shares of common stock sold in this offering (including the shares of common stock issuable
upon the exercise of the Pre-Funded Warrants), at an exercise price of $ per share, which represents 125% of the public offering price
per share and accompanying Common Warrant. The registration statement of which this prospectus forms a part also registers the offer and
sale of these placement agent warrants and the shares of common stock issuable upon exercise of these placement agent warrants. For a
description of compensation to be received by the placement agent, see &ldquo;Plan of Distribution&rdquo; for more information.</P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">(2)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Because there is no minimum number of securities or amount of proceeds required as a condition to closing in this offering, the actual public offering amount, placement agent fees, and proceeds to us, if any, are not presently determinable and may be substantially less than the total maximum offering amounts set forth above. For more information, see &ldquo;Plan of Distribution.&rdquo;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The delivery of the shares of common stock and
any Pre-Funded Warrants and Common Warrants to purchasers is expected to be made on or about  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2025, subject to satisfaction of customary
closing conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Neither the Securities and Exchange Commission
nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus.
Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The date of this prospectus is &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2025.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS<SUP></SUP></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><B>Page</B></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#a_001">ABOUT THIS PROSPECTUS</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">ii</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#a_002">CAUTIONARY NOTE CONCERNING FORWARD-LOOKING STATEMENTS</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">iii</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#a_003">PROSPECTUS SUMMARY</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">1</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#a_004">THE OFFERING</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">4</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#a_005">RISK FACTORS</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">6</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#a_006">USE OF PROCEEDS</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">9</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#a_007">DILUTION</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">10</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#a_008">DESCRIPTION OF CAPITAL STOCK</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">11</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#a_009">DESCRIPTION OF SECURITIES WE ARE OFFERING</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">14</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#a_010">PLAN OF DISTRIBUTION</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">17</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#a_011">INFORMATION INCORPORATED BY REFERENCE</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">20</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#a_012">WHERE YOU CAN FIND MORE INFORMATION</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">21</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF; text-align: left"><A HREF="#a_013">LEGAL MATTERS</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF; text-align: center">21</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#a_014">EXPERTS</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">21</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_001"></A>ABOUT THIS PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We incorporate by reference important information
into this prospectus. You may obtain the information incorporated by reference without charge by following the instructions under &ldquo;Where
You Can Find More Information.&rdquo; You should carefully read this prospectus as well as additional information described under &ldquo;Information
Incorporated by Reference,&rdquo; before deciding to invest in our securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have not, and the placement agent has not,
authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any free
writing prospectuses prepared by or on behalf of us or to which we have referred you. We take no responsibility for and can provide no
assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the securities
offered hereby, and only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus
or in any applicable free writing prospectus is current only as of its date, regardless of its time of delivery or any sale of our securities.
Our business, financial condition, results of operations and prospects may have changed since that date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The information incorporated by reference or provided
in this prospectus contains statistical data and estimates, including those relating to market size and competitive position of the markets
in which we participate, that we obtained from our own internal estimates and research, as well as from industry and general publications
and research, surveys and studies conducted by third parties. Industry publications, studies and surveys generally state that they have
been obtained from sources believed to be reliable. While we believe our internal company research is reliable and the definitions of
our market and industry are appropriate, neither this research nor these definitions have been verified by any independent source.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For investors outside the United States: We have
not, and the placement agent has not, done anything that would permit this offering or possession or distribution of this prospectus in
any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come
into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the securities
and the distribution of this prospectus outside the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus and the information incorporated
by reference into this prospectus contain references to our trademarks and to trademarks belonging to other entities. Solely for convenience,
trademarks and trade names referred to in this prospectus and the information incorporated by reference into this prospectus, including
logos, artwork, and other visual displays, may appear without the &reg; or TM symbols, but such references are not intended to indicate,
in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensor to
these trademarks and trade names. We do not intend our use or display of other companies&rsquo; trade names or trademarks to imply a relationship
with, or endorsement or sponsorship of us by, any other company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_002"></A>CAUTIONARY NOTE CONCERNING FORWARD-LOOKING STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except for historical information, this prospectus
contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;). Forward-looking statements include statements with respect
to our beliefs, plans, objectives, goals, expectations, anticipations, assumptions, estimates, intentions and future performance, and
involve known and unknown risks, uncertainties and other factors, which may be beyond our control, and which may cause our actual results,
performance or achievements to be materially different from future results, performance or achievements expressed or implied by such forward-looking
statements. All statements other than statements of historical fact are statements that could be forward-looking statements. You can identify
these forward-looking statements through our use of words such as &ldquo;may,&rdquo; &ldquo;can,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;assume,&rdquo;
&ldquo;should,&rdquo; &ldquo;indicate,&rdquo; &ldquo;would,&rdquo; &ldquo;believe,&rdquo; &ldquo;contemplate,&rdquo; &ldquo;expect,&rdquo;
&ldquo;seek,&rdquo; &ldquo;estimate,&rdquo; &ldquo;continue,&rdquo; &ldquo;plan,&rdquo; &ldquo;point to,&rdquo; &ldquo;project,&rdquo;
&ldquo;predict,&rdquo; &ldquo;could,&rdquo; &ldquo;intend,&rdquo; &ldquo;target,&rdquo; &ldquo;potential&rdquo; and other similar words
and expressions of the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are a number of important factors that could
cause the actual results to differ materially from those expressed in any forward-looking statement made by us. These factors include,
but are not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>




<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our lack of operating history;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">the expectation that we will incur significant operating losses for the foreseeable future and will need
significant additional capital;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">the period over which we estimate our existing cash and cash equivalents will be sufficient to fund our
future operating expenses and capital expenditure requirements;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">our plans to develop and commercialize our product candidates involves a lengthy and expensive process,
with an uncertain outcome;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">the initiation, enrollment, timing, progress, results, and cost of our research and development programs
and our current and future preclinical studies and clinical trials, including statements regarding the timing of initiation and completion
of studies or trials and related preparatory work, the period during which the results of the trials will become available;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">the timing of interim data and final results from our clinical trials for PAS-004;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">the potential safety and efficacy of our product candidates and the therapeutic implications of clinical
and preclinical data;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">potential impacts of increased trade tariffs, import quotas or other trade restrictions or measures taken
by the United States and other countries, including the recent and potential changes in U.S. trade policies that may be made by the Trump
presidential administration;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">the timing and focus of our future preclinical studies and clinical trials, and the reporting of data
from those studies and trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">the size of the market opportunity for our future product candidates, including our estimates of the number
of patients who suffer from the diseases we are targeting;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">the success of competing therapies that are or may become available;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">the beneficial characteristics, safety, efficacy and therapeutic effects of our future product candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">our ability to obtain and maintain regulatory approval of our future product candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">our plans relating to the further development of our future product candidates, including additional disease
states or indications we may pursue;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">existing regulations and regulatory developments in the United States and other jurisdictions;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">our dependence on third parties;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">the need to hire additional personnel and our ability to attract and retain such personnel;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">our plans and ability to obtain or protect intellectual property rights, including extensions of patent
terms where available and our ability to avoid infringing the intellectual property rights of others;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">our financial performance and sustaining an active trading market for our common stock and our existing
publicly traded warrants;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">our ability to restructure our operations to comply with any potential future changes in government regulation;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">the impact of global economic and market conditions and political developments on our business, including,
among others, rising inflation and capital market disruptions, economic sanctions, bank failures, regional conflicts around the world,
and economic slowdowns or recessions that may result from such developments which could harm our research and development efforts as well
as the value of our common stock and our ability to access capital markets; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">other factors discussed in our most recent Annual Report on Form 10-K.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The foregoing does not represent an exhaustive
list of matters that may be covered by the forward-looking statements contained herein or risk factors that we are faced with that may
cause our actual results to differ from those anticipated in such forward-looking statements. The events and circumstances reflected in
our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking
statements. You should refer to the &ldquo;Risk Factors&rdquo; section of this prospectus for a discussion of important factors that may
cause our actual results to differ materially from those expressed or implied by our forward-looking statements. You should review the
factors and risks and other information we describe in the reports we will file from time to time with the Securities and Exchange Commission
(the &ldquo;SEC&rdquo;) after the date of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All forward-looking statements are expressly qualified
in their entirety by this cautionary note. You are cautioned to not place undue reliance on any forward-looking statements, which speak
only as of the date of this prospectus or the date of the document incorporated by reference into this prospectus. You should read this
prospectus and the documents that we reference in this prospectus and have filed as exhibits to the registration statement, of which this
prospectus is a part, completely and with the understanding that our actual future results may be materially different from what we expect.
We have no obligation, and expressly disclaims any obligation, to update, revise or correct any of the forward-looking statements, whether
as a result of new information, future events or otherwise. We have expressed our expectations, beliefs and projections in good faith
and believe they have a reasonable basis. However, we cannot assure you that our expectations, beliefs or projections will result or be
achieved or accomplished.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5.4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="a_003"></A>PROSPECTUS SUMMARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>This summary highlights information about our
company, this offering and information contained in greater detail in other parts of this prospectus or incorporated by reference into
this prospectus from our filings with the SEC listed in the section titled &ldquo;Information Incorporated by Reference.&rdquo; Because
it is only a summary, it does not contain all of the information that you should consider before purchasing our securities in this offering
and it is qualified in its entirety by, and should be read in conjunction with, the more detailed information appearing elsewhere or incorporated
by reference into this prospectus. You should read the entire prospectus, the registration statement of which this prospectus is a part,
and the information incorporated by reference into this prospectus in their entirety, including the &ldquo;Risk Factors&rdquo; and our
financial statements and the related notes incorporated by reference into this prospectus, before purchasing our securities in this offering.
Except as otherwise indicated herein or as the context otherwise requires, references in this prospectus to &ldquo;Pasithea Therapeutics&rdquo;
&ldquo;the Company,&rdquo; &ldquo;we,&rdquo; &ldquo;us&rdquo; and &ldquo;our&rdquo; refer to Pasithea Therapeutics Corp.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Corporate Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a clinical-stage biotechnology company
focused on the discovery, research and development of innovative treatments for central nervous system (CNS) disorders and other diseases,
including RASopathies and certain cancers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are advancing a pipeline of three therapeutic
product candidates, with a focus on our lead product candidate, PAS-004, a next-generation macrocyclic (as defined below) mitogen-activated
protein kinase, or MEK inhibitor, that we believe may address the limitations and liabilities associated with existing drugs with a similar
mechanism of action. PAS-004 is a small molecule allosteric inhibitor of MEK 1 and 2 for potential use in the treatment of a range of
RASopathies, including neurofibromatosis type 1 (&ldquo;NF1&rdquo;), a number of MAPK pathway driven tumors, such as BRAFv600 and BRAF
fusion tumors, among other indications including ETS2 driven diseases, such as inflammatory bowel disease, primary sclerosing cholangitis
and ankylosing spondylitis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2023, the FDA cleared our Investigational
New Drug application (the &ldquo;IND&rdquo;) for PAS-004 and we received a study may proceed letter for our first-in-human Phase 1 multicenter,
open-label trial of PAS-004 in patients with MAPK pathway-driven advanced tumors with a documented RAS, NF1 or RAF mutation or patients
who have failed BRAF/MEK inhibition (the &ldquo;FIH Phase 1 Dose Escalation Study&rdquo;). We are currently conducting the FIH Phase 1
Dose Escalation Study at four clinical sites in the U.S. and three sites in Eastern Europe. The primary objective of the FIH Phase 1 Dose
Escalation Study is to assess the safety and tolerability of PAS-004 when administered as a single dose (day 1) and as multiple doses
(28-day treatment cycles). Secondary objectives are (I) to characterize the PK profile of PAS-004 when administered as a single dose and
as multiple doses, (ii) to evaluate the pharmacodynamics effect of PAS-004, (iii) to evaluate the preliminary anticancer activity (efficacy)
of PAS- 004 per Response Evaluation Criteria in Solid Tumors 1.1 criteria, and (iv) to define the preliminary recommended Phase 2 dose(s)
of PAS- 004 in adults with MAPK pathway driven advanced solid tumors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 9, 2024, we announced the successful
completion of long-term chronic toxicology studies for PAS-004. On September 26, 2024, we announced safety, tolerability, pharmacokinetic
(PK) and preliminary efficacy data from the first two cohorts of patients in our FIH Phase 1 Dose Escalation Study. To date, we have completed
dosing of a total of 17 patients through cohort 4 (15 mg capsule), including cohort 4b (4 mg tablet) and are currently dosing four patients
in cohort 5 (22 mg capsule). We have observed no dose limiting toxicities, rash or ocular toxicities in any of the cohorts assessed to
date, and all treatment related adverse events have been either Grade 1 or Grade 2, which support PAS-004&rsquo;s potential favorable
safety and tolerability profile. Additionally, PAS-004 has demonstrated favorable PK properties, including a long half-life of approximately
60 hours, a low peak to trough (Cmax to Cmin) ratio as compared to other FDA approved MEK inhibitors, and linear pharmacokinetics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">PAS-004 has received orphan-drug designation from
the FDA for the treatment of NF1. Our clinical development plan for PAS-004 is to advance PAS-004 into a Phase 1/1b clinical trial in
adult NF1-PN patients followed by pediatric NF1-PN patients and ultimately complete registrational clinical trials in these patient populations,
as they represent the initial indication for which we plan to seek marketing approval for PAS-004.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 8; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5.4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our remaining two programs, PAS-003 and PAS-001,
are in the earlier stages of development and are based on novel targets for the treatment of CNS disorders. PAS-003 is being developed
for amyotrophic lateral sclerosis (ALS), while PAS-001 is targeted for schizophrenia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our PAS-003 program aims to develop a proprietary
humanized monoclonal antibody (&ldquo;mAb&rdquo;) with a mechanism-of-action targeting <I>&alpha;</I>5<I>&beta;</I>1 integrin for the
treatment of ALS and potentially address other CNS disorders, such as Multiple Sclerosis (MS) and stroke. We believe targeting <I>&alpha;</I>5<I>&beta;</I>1
integrin may have a beneficial impact on disease due to modulation of multiple cell types and mechanisms involved in neuroinflammation,
which occurs in ALS. We acquired PAS-003 in connection with our acquisition of Alpha-5 Integrin, LLC, a privately held biotechnology company,
in June 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In November 2023, we announced that we selected
our PAS-003 lead development candidate, a humanized monoclonal antibody with optimal properties that targets &alpha;5&beta;1 integrin
for the treatment of both sporadic and familial ALS. PAS-003 is now ready for manufacturing and IND-enabling studies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our PAS-001 discovery program aims to develop
a brain penetrant small molecule targeting the complement component 4A (&ldquo;C4A&rdquo;) for the treatment of schizophrenia. Recent
findings implicate C4A in synaptic loss (fewer connections between nerve cells), which has been shown to occur in schizophrenia. In humans,
structural variation in the complement 4 gene (C4) is an important genetic risk factor for schizophrenia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2023, we determined
to cease further development of our PAS-002 program for multiple sclerosis (&ldquo;MS&rdquo;) due to several factors including the significant
capital, resources and time required to develop the program, and the current and projected availability of effective treatment options
for MS patients, among others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2023, we discontinued
our support services to anti-depression clinics in the U.K. and related at-home services in New York, NY. In addition, we discontinued
our clinical operations in Los Angeles, CA and disposed of the related property. Accordingly, we currently have one reportable segment,
&ldquo;Therapeutics,&rdquo; related to the research and development of our therapeutic product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Private Placement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 26, 2024, we entered into a securities
purchase agreement (the &ldquo;Private Placement&rdquo;) with an institutional investor, pursuant to which we agreed to sell pre-funded
warrants to purchase up to an aggregate of 1,219,513 shares of our common stock at an exercise price of $0.001 per share, Series A warrants
to purchase up to an aggregate of 1,219,513 shares of our common stock at an exercise price of $3.85 per share, and Series B warrants
to purchase up to an aggregate of 1,219,513 shares of our common stock with an exercise price of $3.85 per share. The combined purchase
price per pre-funded warrant and accompanying warrants was $4.099. Aggregate gross proceeds from the Private Placement were approximately
$4.5 million. The Private Placement closed on September 30, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Reverse Stock Split</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 28, 2023, we filed a Certificate of
Amendment to our Certificate of Incorporation (as defined below) reflecting a one-for-20 reverse stock split of our issued and outstanding
shares of common stock which became effective at 12:01 a.m. Eastern Time on January 2, 2024 (the &ldquo;Reverse Stock Split&rdquo;). As
a result of the Reverse Stock Split, every 20 shares of common stock issued and outstanding were converted into one share of Common Stock,
with a corresponding reduction in the number of authorized shares of common stock from 495,000,000 to 100,000,000. The Reverse Stock Split
affected all stockholders uniformly and did not alter any stockholder&rsquo;s percentage interest in our equity, except to the extent
that the Reverse Stock Split resulted in some stockholders owning a fractional share. No fractional shares were issued in connection with
the Reverse Stock Split and stockholders who were otherwise entitled to receive a fractional share instead received a cash payment. All
outstanding securities entitling their holders to purchase shares of common stock or acquire shares of common stock, including stock options,
convertible debt and warrants, were adjusted as a result of the Reverse Stock Split, as required by the terms of those securities. Unless
otherwise noted, the share and per share information in this prospectus reflects the Reverse Stock Split.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5.4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Implications of Being an Emerging Growth Company
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are an emerging growth company as defined in
the Jumpstart Our Business Startups Act of 2012. We will remain an emerging growth company until the earliest to occur of: the last day
of the fiscal year in which we have more than $1.235 billion in annual revenues; the date we qualify as a &ldquo;large accelerated filer&rdquo;;
the issuance, in any three-year period, by us of more than $1.0 billion in non-convertible debt securities; and the last day of the fiscal
year ending after the fifth anniversary of our first sale of common equity securities pursuant to a U.S. registration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As an emerging growth company, we may take advantage
of certain exemptions from various reporting requirements that are applicable to other publicly traded entities that are not emerging
growth companies. These exemptions include: (i) the option to present only two years of audited financial statements and related discussion
in the section titled &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&rdquo; in our
filings with the SEC; (ii) not being required to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley
Act of 2002; (iii) not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board,
or PCAOB, regarding mandatory audit firm rotation or a supplement to the auditor&rsquo;s report providing additional information about
the audit and the financial statements (i.e., an auditor discussion and analysis); (iv) not being required to submit certain executive
compensation matters to shareholder advisory votes, such as &ldquo;say-on-pay,&rdquo; &ldquo;say-on-frequency,&rdquo; and &ldquo;say-on-golden
parachutes&rdquo;; and (v) not being required to disclose certain executive compensation related items such as the correlation between
executive compensation and performance and comparisons of the chief executive officer&rsquo;s compensation to median employee compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Implications of Being a Smaller Reporting Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are a &ldquo;smaller reporting company&rdquo; as defined in Item
10(f)(1) of Regulation S-K. Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among
other things, providing only two years of audited financial statements. We will remain a smaller reporting company until the last day
of any fiscal year for so long as either (1) the market value of our shares of common stock held by non-affiliates does not equal or exceed
$250.0 million as of the prior June 30th, or (2) our annual revenues did not equal or exceed $100.0 million during such completed fiscal
year and the market value of our shares of common stock held by non-affiliates did not equal or exceed $700.0 million as of the prior
June 30th. To the extent we take advantage of any reduced disclosure obligations, it may make comparison of our financial statements with
other public companies difficult or impossible.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We were formed as a Delaware corporation in May
2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;Pasithea&rdquo; and our other common law
trademarks, service marks or trade names appearing herein are the property of Pasithea Therapeutics Corp. We do not intend the use or
display of other companies&rsquo; trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any
other companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our mailing address is 1111 Lincoln Road, Suite
500, Miami Beach, FL 33139 and our telephone number is (786) 977-3380. Our website address is www.pasithea.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Information contained in, or accessible through,
our website does not constitute part of this prospectus or registration statement and inclusions of our website address in this prospectus
or registration statement are inactive textual references only. You should not rely on any such information in making your decision whether
to purchase our securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</DIV>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
</P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<DIV STYLE="padding: 5.4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="padding: 1.5pt">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_004"></A>THE
OFFERING</B></P>
</TD></TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="vertical-align: top; padding: 1.5pt; text-align: left; width: 25%"><B>Common Stock to be Offered </B>&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: justify; width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt; text-align: justify; width: 73%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares based on the sale of our common stock at an assumed combined public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share of common stock and accompanying Common Warrant, which is the closing price of our common stock on &nbsp;&nbsp;&nbsp;&nbsp;, 2025, and no sale of any Pre-Funded Warrants.</TD></TR>
  <TR>
    <TD STYLE="padding: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding: 1.5pt; text-align: left"><B>Pre-Funded Warrants to be Offered </B></TD>
    <TD STYLE="padding: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are also offering to certain purchasers whose
    purchase of shares of common stock in this offering would otherwise result in the purchaser, together with its affiliates and certain
    related parties, beneficially owning more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding common stock immediately
    following the consummation of this offering, the opportunity to purchase, if such purchasers so choose, Pre-Funded Warrants to purchase
    shares of common stock, in lieu of shares of common stock that would otherwise result in any such purchaser&rsquo;s beneficial ownership
    exceeding 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding common stock. Each Pre-Funded Warrant will be exercisable
    for one share of our common stock. The purchase price of each Pre-Funded Warrant and accompanying Common Warrant will equal the price
    at which the share of common stock and accompanying Common Warrant are being sold to the public in this offering, minus $0.001, and the
    exercise price of each Pre-Funded Warrant will be $0.001 per share. The Pre-Funded Warrants will be exercisable immediately and may be
    exercised at any time until all of the Pre-Funded Warrants are exercised in full. This offering also relates to the shares of common stock
    issuable upon exercise of the Pre-Funded Warrants sold in this offering.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For each Pre-Funded Warrant we sell, the number
    of shares of common stock we are offering will be decreased on a one-for-one basis. Because we will issue a Common Warrant for each share
    of our common stock and for each Pre-Funded Warrant to purchase one share of our common stock sold in this offering, the number of Common
    Warrants sold in this offering will not change as a result of a change in the mix of the shares of our common stock and Pre-Funded Warrants
    sold.</P></TD></TR>
  <TR>
    <TD STYLE="padding: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding: 1.5pt; text-align: left"><B>Common Warrants to be Offered</B></TD>
    <TD STYLE="padding: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each share of our common stock and each Pre-Funded
    Warrant to purchase one share of our common stock is being sold together with a Common Warrant to purchase one share of our common stock.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each Common Warrant will have an exercise price
of $ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share (representing 100% of the price at which a share of common stock and accompanying Common
Warrant are sold to the public in this offering), will expire on the &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;anniversary of the original issuance
date and be exercisable beginning on the effective date of Warrant Stockholder Approval; <U>provided</U>, <U>however</U>, that if the
Pricing Conditions are met, the Common Warrants will be exercisable upon issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The shares of common stock and Pre-Funded Warrants,
    and the accompanying Common Warrants, as the case may be, can only be purchased together in this offering but will be issued separately
    and will be immediately separable upon issuance. This prospectus also relates to the offering of the shares of common stock issuable upon
    exercise of the Common Warrants.</P></TD></TR>

<TR>
    <TD STYLE="vertical-align: top; padding: 1.5pt; text-align: left; width: 25%"><B>Placement Agent Warrants</B></TD>
    <TD STYLE="padding: 1.5pt; text-align: justify; width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt; text-align: justify; width: 73%"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">We have agreed to issue to the placement agent or its designees warrants,
or the placement agent warrants, to purchase up to 7% of the aggregate number of shares of common stock sold in this offering (or common
stock equivalent but excluding the shares of common stock underlying the Common Warrants (other than the Pre-Funded Warrants) issued in
this offering), at an exercise price equal to 125% of the public offering price per share and accompanying Common Warrant to be sold in
this offering. The placement agent warrants will be exercisable beginning on the effective date of Warrant Stockholder Approval; <U>provided</U>,
<U>however</U>, that if the Pricing Conditions are met, the placement agent warrants will be exercisable upon issuance. The placement
agent warrants will expire five years from the commencement of sales under this offering.</P></TD></TR>
  <TR>
    <TD STYLE="padding: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding: 1.5pt; text-align: left"><B>Common Stock to be Outstanding Immediately After this Offering<FONT STYLE="font-size: 10pt"><SUP>(1)</SUP></FONT></B></TD>
    <TD STYLE="padding: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt; text-align: justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares, (assuming we sell only shares of common stock and no Pre-Funded Warrants and assuming no exercise of the Common Warrants).</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

</DIV>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<DIV STYLE="padding: 5.4pt; border: Black 1.5pt solid">

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="vertical-align: top; padding: 1.5pt; text-align: justify; width: 25%"><B>Use of Proceeds </B></TD>
    <TD STYLE="padding: 1.5pt; text-align: justify; width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt; width: 73%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We estimate that the net proceeds from this offering
    will be approximately $  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, based on an assumed combined public offering price of $  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share of common stock and accompanying Common
    Warrants which was the closing price of our common stock on Nasdaq on  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2025, after deducting the placement agent fees and estimated offering
    expenses payable by us, and assuming we sell only shares of common stock and no Pre-Funded Warrants and excluding the proceeds, if any,
    from the exercise of the Common Warrants in this offering.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We currently intend to use the net proceeds from
    the offering for general corporate purposes, which includes, without limitation, ongoing research and pre-clinical studies, clinical trials,
    the development of new biological and pharmaceutical technologies, investing in or acquiring companies that are synergistic with or complementary
    to our technologies, licensing activities related to our current and future product candidates, and to the development of emerging technologies,
    investing in or acquiring companies that are developing emerging technologies, licensing activities, or the acquisition of other businesses
    and working capital. See &ldquo;Use of Proceeds&rdquo; for additional information.</P></TD></TR>
  <TR>
    <TD STYLE="padding: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding: 1.5pt; text-align: justify"><B>Risk Factors </B></TD>
    <TD STYLE="padding: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt; text-align: justify">An investment in our securities involves a high degree of risk. See &ldquo;Risk Factors&rdquo; beginning on page <FONT>6</FONT> of this prospectus and the other information included and incorporated by reference in this prospectus for a discussion of the risk factors you should carefully consider before deciding to invest in our securities.</TD></TR>
  <TR>
    <TD STYLE="padding: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding: 1.5pt; text-align: left"><B>National Securities Exchange Listing </B></TD>
    <TD STYLE="padding: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt; text-align: justify">Our common stock and certain of our outstanding warrants are currently listed on Nasdaq under the symbols &ldquo;KTTA&rdquo; and &ldquo;KTTAW,&rdquo; respectively. There is no established public trading market for the Pre-Funded Warrants or Common Warrants, and we do not expect a market to develop. In addition, we do not intend to apply to list the Pre-Funded Warrants or Common Warrants on the Nasdaq Capital Market or on any other national securities exchange or other nationally recognized trading system. Without an active trading market, the liquidity of the Pre-Funded Warrants and Common Warrants will be limited.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="padding: 1.5pt; text-align: left; width: 0.25in">(1)</TD>
    <TD STYLE="padding: 1.5pt; text-align: left">The above discussion and table are based on 2,705,263 shares outstanding as of March 24, 2025, and excludes:</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">164,846
    shares of common stock issuable upon exercise of stock options, at a weighted-average exercise price of $22.41 per share;</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,293,692
    shares of common stock issuable upon exercise of currently outstanding warrants, at a weighted-average exercise price of $15.62 per
    share;</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">165,875
    shares of our common stock that are available for future issuance under our 2023 Stock Incentive Plan (the &quot;2023 Plan&quot;)
    or shares that will become available under our 2023 Plan;</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    shares of common stock issuable upon exercise of the Common Warrants and/or Pre-Funded Warrants to be issued to investors in this
    offering; and</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; padding: 1.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    shares of common stock issuable upon the exercise of warrants to be issued to the placement agent or its designees in connection
    with this offering.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</DIV>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_005"></A>RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Before purchasing any of the securities you
should carefully consider the risk factors set forth below and incorporated by reference in this prospectus from our Annual Report on
Form 10-K for the fiscal year ended December 31, 2024, and any subsequent updates described in our Quarterly Reports on Form 10-Q and
Current Reports on Form 8-K, as well as the risks, uncertainties and additional information set forth in our SEC reports on Forms 10-K,
10-Q, and 8-K and in the other documents incorporated by reference in this prospectus. For a description of these reports and documents,
and information about where you can find them, see &ldquo;Additional Information&rdquo; and &ldquo;Incorporation of Certain Information
By Reference.&rdquo; Additional risks not presently known or that we presently consider to be immaterial could subsequently materially
and adversely affect our financial condition, results of operations, business, and prospects.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We have incurred losses since inception
and anticipate that we will continue to incur losses for the foreseeable future. We are not currently profitable, and we may never achieve
or sustain profitability.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have never generated revenue from operations,
are unlikely to generate revenues for several years, and are currently operating at a loss and expect our operating costs will increase
significantly as we incur costs related to preclinical development, the clinical trials for our drug candidates and to operating as a
public company. We expect to incur substantial expenses without corresponding revenues unless and until we are able to obtain regulatory
approval and successfully commercialize one or more of our drug candidates. We may never be able to obtain regulatory approval for the
marketing of any of our drug candidates in any indication in the United States or internationally. Even if we are able to commercialize
our drug candidates, there can be no assurance that we will generate significant revenues or ever achieve profitability. We have incurred
losses in each year since we commenced operations. We incurred net losses of approximately $13.9 million and approximately $16.0 million
for the years ended December 31, 2024, and 2023, respectively. As of December 31, 2024, we had an accumulated deficit of approximately
$49.6 million. The size of our future net losses will depend, in part, on our future expenses and our ability to generate revenue, if
any. Revenue from our current and potential future collaborations is uncertain because milestones or other contingent payments under our
agreements may not be achieved or received.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2024, we had capital resources
consisting of cash and cash equivalents of $6.9 million. We will continue to expend substantial cash resources for the foreseeable future
for the clinical development of our product candidates and development of any other indications and product candidates we may choose to
pursue. These expenditures will include costs associated with research and development, conducting preclinical studies and clinical trials,
manufacturing and supply, as well as marketing and selling any products approved for sale. In particular, our Phase 3 clinical studies
for our product candidates will require substantial funds to complete. Because the conduct and results of any clinical trial are highly
uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of
our current and any future product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are uncertain when or if we will be able to
achieve or sustain profitability. If we achieve profitability in the future, we may not be able to sustain profitability in subsequent
periods. Failure to become and remain profitable would impair our ability to sustain operations and adversely affect the price of our
securities and our ability to raise capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We will require additional capital to fund
our operations, and if we fail to obtain necessary financing, we may not be able to complete the development and commercialization of
our drugs. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe that our existing cash and cash equivalents,
together with interest or dividends thereon, before giving effect to the proceeds of this offering, will be sufficient to fund our operations
into June 2025. We have based these estimates, however, on assumptions that may prove to be wrong, and we could spend our available capital
resources much faster than we currently expect or require more capital to fund our operations than we currently expect. Our currently
anticipated expenditures for the development of our product candidates, PAS-004, PAS-003, and PAS-001, exceed our existing cash resources.
Even after the completion of this offering, we will need to raise additional capital to fund our operations and continue to support our
planned development and commercialization activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The report of our independent registered
public accounting firms for the fiscal year ended December 31, 2024 contains an explanatory paragraph regarding substantial doubt about
our ability to continue as a&nbsp;going concern.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Due to the uncertainty of our ability to meet
our current operating and capital expenses, in its report on our audited annual financial statements as of and for the year ended December
31, 2024, our independent audit firm included an explanatory paragraph regarding concerns about our ability to continue as a&nbsp;going
concern. Substantial doubt about our ability to continue as a&nbsp;going concern&nbsp;may materially and adversely affect the price per
share of our common stock and certain of our warrants and we may have a more difficult time obtaining financing. Further, the perception
that we may be unable to continue as a&nbsp;going concern&nbsp;may impede our ability to raise additional funds or operate our business
due to concerns regarding our ability to discharge our contractual obligations. In addition, as an &ldquo;best efforts offering&rdquo;
in which no minimum number or dollar amount of securities is required to be sold, we may be unable to raise sufficient capital to extend
our cash runway beyond June 2025.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We have broad discretion in the use of the
net proceeds from this offering and may not use them effectively.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our management will have broad discretion in the
application of the net proceeds, including for any of the purposes described in the section of this prospectus titled &ldquo;Use of Proceeds&rdquo;.
You will be relying on the judgment of our management with regard to the use of these net proceeds, and you will not have the opportunity,
as part of your investment decision, to assess whether the net proceeds are being used appropriately. The failure by our management to
apply these funds effectively could result in financial losses that could have a material adverse effect on our business, cause the price
of our securities to decline and delay the development of our product candidates. Pending the application of these funds, we may invest
the net proceeds from this offering in a manner that does not produce income or that loses value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>You will experience immediate and substantial
dilution in the net tangible book value of the shares you purchase in this offering and may experience additional dilution in the future.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The combined public offering price per share of
common stock and related Common Warrant, and the combined public offering price of each Pre-Funded Warrant and related Common Warrant,
will be substantially higher than the as adjusted net tangible book value per share of our common stock after giving effect to this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Assuming the sale of shares of our common stock
and Common Warrants to purchase up to shares of common stock at an assumed combined public offering price of $ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share and related Common
Warrant, the closing sale price per share of our common stock on Nasdaq on March  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2025, assuming no sale of any Pre-Funded Warrants in
this offering, no exercise of the Common Warrants being offered in this offering and after deducting the placement agent fees and commissions
and estimated offering expenses payable by us, you will incur immediate dilution of approximately $  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share. As a result of the dilution
in net tangible book value to investors purchasing securities in this offering, investors may receive significantly less than the purchase
price paid in this offering, if anything, in the event of the liquidation of our company. See the section titled &ldquo;Dilution&rdquo;
below for a more detailed discussion of the dilution you will incur if you participate in this offering. To the extent shares are issued
under outstanding options and warrants at exercise prices lower than the public offering price of our common stock in this offering, including
the shares underlying the Pre-Funded Warrants, holders will incur further dilution. &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>There is no public market for the Common
Warrants or Pre-Funded Warrants being offered by us in this offering.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There is no established public trading market
for the Common Warrants or the Pre-Funded Warrants, and we do not expect a market to develop. In addition, we do not intend to apply to
list the Common Warrants or Pre-Funded Warrants on the Nasdaq Capital Market or any other national securities exchange or other nationally
recognized trading system. Without an active market, the liquidity of the Common Warrants and Pre-Funded Warrants will be limited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The Common Warrants and Pre-Funded Warrants
are speculative in nature.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Common Warrants and Pre-Funded Warrants offered
hereby do not confer any rights of share of common stock ownership on their holders, such as voting rights, but rather merely represent
the right to acquire shares of common stock at a fixed price. Specifically, commencing on the date of issuance, holders of the Common
Warrants may acquire the shares of common stock issuable upon exercise of such warrants at an exercise price of $  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share of common
stock, and holders of the Pre-Funded Warrants may acquire the shares of common stock issuable upon exercise of such warrants at an exercise
price of $0.001 per share of common stock. Moreover, following this offering, the market value of the Common Warrants and Pre-Funded Warrants
is uncertain and there can be no assurance that the market value of the Common Warrants or Pre-Funded Warrants will equal or exceed their
respective public offering prices. There can be no assurance that the market price of the shares of common stock will ever equal or exceed
the exercise price of the Common Warrants or Pre-Funded Warrants, and consequently, whether it will ever be profitable for holders of
Common Warrants to exercise the Common Warrants or for holders of the Pre-Funded Warrants to exercise the Pre-Funded Warrants.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Holders of the Pre-Funded Warrants and the
Common Warrants offered hereby will have no rights as common stockholders with respect to the shares our common stock underlying the warrants
until such holders exercise their warrants and acquire our common stock, except as otherwise provided in the Pre-Funded Warrants and the
Common Warrants.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Until holders of the Common Warrants and the Pre-Funded
Warrants acquire shares of our common stock upon exercise thereof, such holders will have no rights with respect to the shares of our
common stock underlying such warrants, except to the extent that holders of such Common Warrants and Pre-Funded Warrants will have certain
rights to participate in distributions or dividends paid on our common stock as set forth in the Common Warrants and the Pre-Funded Warrants.
Upon exercise of the Common Warrants and the Pre-Funded Warrants, the holders will be entitled to exercise the rights of a common stockholder
only as to matters for which the record date occurs after the exercise date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The Common Warrants are not exercisable
until the Warrant Stockholder Approval; provided, however, that if the Pricing Conditions are met, the Common Warrants will be exercisable
upon issuance.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Common Warrants will have an exercise price
of $&nbsp;&nbsp;&nbsp;&nbsp; per share and will be exercisable beginning on the effective date of the Warrant Stockholder Approval; <U>provided</U>,
<U>however</U>, that if the Pricing Conditions are met, the Common Warrants will be exercisable upon issuance (the &ldquo;Initial Exercise
Date&rdquo;). The Common Warrants will expire on&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; -year anniversary of the
Initial Exercise Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">While we intend to promptly seek Warrant Stockholder
Approval, there is no guarantee that the Warrant Stockholder Approval will ever be obtained. If we are unable to obtain the Warrant Stockholder
Approval, the Common Warrants may have no value.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Purchasers who purchase our securities in
this offering pursuant to a securities purchase agreement may have rights not available to purchasers who purchase without the benefit
of a securities purchase agreement.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to rights and remedies available to
all purchasers in this offering under federal securities and state law, the purchasers who enter into a securities purchase agreement
will also be able to bring claims of breach of contract against us. The ability to pursue a claim for breach of contract provides those
investors with the means to enforce the covenants uniquely available to them under the securities purchase agreement including, but not
limited to: (i)&nbsp;timely delivery of securities; (ii)&nbsp;agreement to not enter into variable rate financings for one&nbsp;year from
closing, subject to certain exceptions; (iii)&nbsp;agreement to not enter into any financings for 90&nbsp;days from closing, subject to
certain exceptions; and (iv)&nbsp;indemnification for breach of contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>This is a best efforts offering, with no
minimum amount of securities is required to be sold, and we may not raise the amount of capital we believe is required for our business
plans, including our near-term business plans.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The placement agent has agreed to use its reasonable
best efforts to solicit offers to purchase the securities in this offering. The placement agent has no obligation to buy any of the securities
from us or to arrange for the purchase or sale of any specific number or dollar amount of the securities. There is no required minimum
number of securities that must be sold as a condition to completion of this offering. Because there is no minimum offering amount required
as a condition to the closing of this offering, the actual offering amount, placement agent fees and proceeds to us are not presently
determinable and may be substantially less than the maximum amounts set forth above. We may sell fewer than all of the securities offered
hereby, which may significantly reduce the amount of proceeds received by us, and investors in this offering will not receive a refund
in the event that we do not sell an amount of securities sufficient to support our continued operations, including our near-term continued
operations. Thus, we may not raise the amount of capital we believe is required for our operations in the short-term and may need to raise
additional funds, which may not be available or available on terms acceptable to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our failure to maintain compliance with
Nasdaq&rsquo;s continued listing requirements could result in the desilting of our securities.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our common stock is currently listed on the Nasdaq
Capital Market. Continued listing of a security on Nasdaq Capital Market is conditioned upon compliance with various continued listing
standards. In the past, we have received notices from Nasdaq&rsquo;s Listing Qualifications Department indicating that we had not complied
with certain of the Nasdaq Capital Market&rsquo;s continued listing standards. While we have regained compliance for each instance, there
can be no assurance that we will continue to maintain compliance with the Nasdaq listing requirements. A delisting could substantially
decrease trading in our common stock, adversely affect the market liquidity of our common stock as a result of the loss of market efficiencies
associated with Nasdaq and the loss of federal preemption of state securities laws, adversely affect our ability to obtain financing on
acceptable terms, if at all, and may result in the potential loss of confidence by investors, suppliers, and employees and lead to fewer
business development opportunities. Additionally, the market price of our common stock may decline further, and stockholders may lose
some or all of their investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event of a delisting, we anticipate that
we would take actions to restore our compliance with the Nasdaq Capital Market or another national exchange&rsquo;s listing requirements,
but we can provide no assurance that any such action taken by us would allow our common stock to regain listing on the Nasdaq Capital
Market, stabilize our market price, improve the liquidity of our common stock, prevent our common stock from dropping below the Nasdaq
Capital Market&rsquo;s minimum bid price requirement, or prevent future non-compliance with the Nasdaq Capital Market or another national
securities exchange&rsquo;s listing requirements.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_006"></A>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We estimate that the net proceeds from the offering
will be approximately $  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming a combined public offering price per share of common stock and accompanying Common Warrant of
$  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, the closing price per share of our common stock on Nasdaq on March  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2025, after deducting the placement agent fees and estimated
offering expenses payable by us, assuming no sale of any fixed combinations of Pre-Funded Warrants and Common Warrants offered hereunder
and excluding the proceeds, if any, from the exercise of the Common Warrants issued in this offering. If the Common Warrants are exercised
in full for cash, the estimated net proceeds will increase to $  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. However, because this is a best efforts offering and there is no minimum
offering amount required as a condition to the closing of this offering, the actual offering amount, the placement agent&rsquo;s fees
and net proceeds to us are not presently determinable and may be substantially less than the maximum amounts set forth on the cover page
of this prospectus. In addition, we may receive proceeds from the exercise of the placement agent warrants, to the extent such placement
agent warrants are exercised for cash, but we will not receive any proceeds from any sale of the shares underlying the placement agent
warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We intend to use the net proceeds from the offering
for general corporate purposes, which includes, without limitation, ongoing research and pre-clinical studies, clinical trials, the development
of new biological and pharmaceutical technologies, investing in or acquiring companies that are synergistic with or complementary to our
technologies, licensing activities related to our current and future product candidates, and to the development of emerging technologies,
investing in or acquiring companies that are developing emerging technologies, licensing activities, or the acquisition of other businesses
and working capital. These expected uses represent our intentions based upon our current plans and business conditions, which could change
in the future as our plans and business conditions evolve.&nbsp;The amounts and timing of these expenditures will depend on numerous factors,
including the development of our current business initiatives. We have no specific acquisition contemplated at this time. As of the date
of this prospectus, we cannot specify with certainty all of the particular uses for the net proceeds from this offering. As a result,
our management will have broad discretion in the application of the net proceeds from this offering, and the investors will be relying
on the judgment of our management regarding the application of the net proceeds from this offering. The amounts and timing of our actual
expenditures will depend on numerous factors, including factors described under &ldquo;Risk Factors&rdquo; in this prospectus and the
documents incorporated by reference herein and therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_007"></A>DILUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If you invest in our securities in this offering,
your interest will be diluted immediately to the extent of the difference between the public offering price paid by the purchasers of
the shares of common stock and Common Warrants sold in this offering and the as-adjusted net tangible book value per shares of common
stock after this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The net tangible book value of our common stock
as of December 31, 2024, was approximately $6.2 million, or approximately $4.45 per share of common stock. Net tangible book value per
share represents the amount of our total tangible assets less total liabilities divided by the total number of our shares of common stock
outstanding as of December 31, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">After giving effect to the sale by us in this
offering of shares of common stock and accompanying Common Warrants at a price per share and accompanying Common Warrant of $ , our as
adjusted net tangible book value as of December 31, 2024, would have been approximately $ million, or approximately $  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share of common
stock. This represents an immediate increase in net tangible book value of approximately $  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share of common stock to our existing security
holders and an immediate dilution in as adjusted net tangible book value of approximately $  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share of common stock to purchasers of
common stock in this offering, as illustrated by the following table:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Assumed public offering price per share and accompanying Common Warrant</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">$</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 88%">Historical net tangible book value per share as of December 31, 2024</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">4.45</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Increase in net tangible book value per share attributable to new investors</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">As adjusted net tangible book value per share as of December 31, 2024 after, giving effect to this offering</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> &nbsp;</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Dilution per share to new investors purchasing common stock in this offering</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with the rules of the SEC, in the
event that the actual combined public offering per share of common stock and accompanying Common Warrant is more or less than the assumed
combined public offering price of $ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share and accompanying Common Warrant (the closing price of our common stock on Nasdaq on March
, 2025), the number of shares and/or Pre-Funded Warrants and Common Warrants we sell may be decreased or increased so long as the aggregate
offering amount does not exceed the total amount registered on the registration statement of which this prospectus forms a part. Assuming
a total offering amount of $  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, for every $0.10 increase in the assumed combined public offering price per share and accompanying Common
Warrant, we would sell  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;fewer shares of common stock and/or Pre-Funded Warrants and Common Warrants and for every $0.10 decrease in the
assumed combined public offering price per share and accompanying Common Warrant, we would sell  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional shares of common stock and/or
Pre-Funded Warrants and Common Warrants. Each $0.10 increase in the assumed combined public offering price per share and accompanying
Common Warrant would increase the as adjusted net tangible book value per share by $  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share and increase the dilution per share to
investors participating in this offering by $ per share after deducting estimated offering expenses payable by us. Each $0.10 decrease
in the assumed combined public offering price per share and accompanying Common Warrant would decrease the as adjusted net tangible book
value per share by $ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share and decrease the dilution per share to investors participating in this offering by $ per share, after deducting
estimated offering expenses payable by us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The table and discussion above are based on 1,394,263
shares of common stock outstanding as of December 31, 2024, and excludes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">182,034
    shares of common stock issuable upon exercise of stock options, at a weighted-average exercise price of $21.17 per share;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 22.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,293,692
    shares of common stock issuable upon exercise of then outstanding warrants, at an exercise price of $15.62 per share;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">871,000
    shares of common stock issuable upon exercise of then outstanding pre-funded warrants issued in the Private Placement;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101,609
    shares of our common stock that are available for future issuance under our 2023 Plan or shares that will become available under
    our 2023 Plan;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 22.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    shares of common stock issuable upon exercise of the Common Warrants and any Pre-Funded Warrants issued to the investors in this
    offering; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 22.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    shares of common stock issuable upon the exercise of warrants to be issued to the placement agent or its designees in connection
    with this offering.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The information discussed above is illustrative
only and will adjust based on the actual public offering price, the actual number of shares and Common Warrants that we offer in this
offering, and other terms of this offering determined at pricing. Except as indicated otherwise, the discussion and table above each assume
(i) no sale of Pre-Funded Warrants, which, if sold, would reduce the number of shares of common stock that we are offering on a one-for-one
basis, (ii) no exercise of Common Warrants accompanying the shares of common stock sold in this offering, and (iii) no exercise of the
warrants to be issued to the placement agent or its designees in connection with this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_008"></A>DESCRIPTION OF CAPITAL STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following summary of the rights of our capital
stock is not complete and is subject to and qualified in its entirety by reference to our Second Amended and Restated Certificate of Incorporation,
as amended (&ldquo;Certificate of Incorporation&rdquo;), and Second Amended and Restated Bylaws (&ldquo;Bylaws&rdquo;), copies of which
are filed as exhibits to our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 24, 2025, and
the forms of securities, copies of which are filed as exhibits to the registration statement of which this prospectus forms a part, which
are incorporated by reference herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are authorized to issue an aggregate of 105,000,000
shares. The authorized capital stock is divided into 100,000,000 shares of common stock having a par value of $0.0001 per share and 5,000,000
shares of preferred stock having a par value of $0.0001 per share. As of March 24, 2025, there were 2,705,263 shares of common stock outstanding.
In addition, as of March 24, 2025, we had outstanding stock options to purchase an aggregate of 164,846 shares of our common stock, at
a weighted average exercise price equal to $22.41 per share. Our authorized but unissued shares of common stock and preferred stock are
available for issuance without further action by our stockholders, unless such action is required by applicable law or the rules of any
stock exchange or automated quotation system on which our securities may be listed or traded in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All shares of our common stock are one and the
same class, identical in all respects and have equal rights, powers and privileges.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Voting</I>. Except as otherwise provided by
law or by the resolution or resolutions providing for the issue of any series of preferred stock, the holders of outstanding shares of
common stock have the exclusive right to vote for the election and removal of directors and for all other purposes. On each matter on
which holders of common stock are entitled to vote, each outstanding share of such common stock is entitled to one vote.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Dividends</I>. Subject to the rights of the
holders of preferred stock, holders of shares of common stock are entitled to receive such dividends and distributions and other distributions
of our cash, stock or property when, as and if declared by our board of directors (the &ldquo;Board&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Liquidation</I>. Subject to the rights of the
holders of preferred stock, shares of common stock are entitled to receive our assets and funds available for distribution in the event
of any liquidation, dissolution or winding up of the affairs of us, whether voluntary or involuntary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Rights and Preferences</I>. Holders of our
common stock will have no preemptive, conversion or subscription rights, and there will be no redemption or sinking funds provisions applicable
to our common stock. The rights, preferences and privileges of the holders of our common stock will be subject to, and may be adversely
affected by, the rights of the holders of share of any series of our preferred stock that we may designate and issue in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Preferred Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Board has the authority, without further action
by our stockholders, to issue up to 5,000,000 shares of preferred stock in one or more classes or series. Our Board is able to determine,
with respect to any series of preferred stock, the powers (including voting powers), preferences and relative, participating, optional
or other special rights, and the qualifications, limitations or restrictions thereof, including, without limitation:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">the designation of the series;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">the number of shares of the series, which our Board may, except where otherwise provided in the preferred
stock designation, increase (but not above the total number of authorized shares of the class) or decrease (but not below the number of
shares then outstanding);</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">whether dividends, if any, will be cumulative or non-cumulative and the dividend rate of the series;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">the dates at which dividends, if any, will be payable;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">the redemption or repurchase rights and price or prices, if any, for shares of the series;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">the terms and amounts of any sinking fund provided for the purchase or redemption of shares of the series;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">the amounts payable on, and the preferences, if any, of shares of the series in the event of any voluntary
or involuntary liquidation, dissolution or winding-up of our affairs;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">whether the shares of the series will be convertible into shares of any other class or series, or any
other security, of us or any other entity, and, if so, the specification of the other class or series or other security, the conversion
price or prices or rate or rates, any rate adjustments, the date or dates as of which the shares will be convertible and all other terms
and conditions upon which the conversion may be made;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">restrictions on the issuance of shares of the same series or of any other class or series;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">the voting rights, if any, of the holders of the series; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">any other powers, preferences and relative, participating, optional or other special rights of each series
of preferred stock, and any qualifications, limitations or restrictions thereof, all as may be determined from time to time by our Board
and stated in the resolution or resolutions providing for the issuance of such preferred stock.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We could issue a series of preferred stock that
could, depending on the terms of the series, impede or discourage an acquisition attempt or other transaction that some, or a majority,
of the holders of our common stock might believe to be in their best interests or in which the holders of our common stock might receive
a premium over the market price of the shares of our common stock. Additionally, the issuance of preferred stock may adversely affect
the rights of holders of our common stock by restricting dividends on the common stock, diluting the voting power of the common stock
or subordinating the liquidation rights of the common stock. As a result of these or other factors, the issuance of preferred stock could
have an adverse impact on the market price of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Anti-Takeover Effects of Delaware law and Our
Certificate of Incorporation and Bylaws</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Certificate of Incorporation, Bylaws and the
Delaware General Corporation Law (the &ldquo;DGCL&rdquo;) contain provisions that are intended to enhance the likelihood of continuity
and stability in the composition of our Board. These provisions are intended to avoid costly takeover battles, reduce our vulnerability
to a hostile or abusive change of control and enhance the ability of our Board to maximize stockholder value in connection with any unsolicited
offer to acquire us. However, these provisions may have an anti-takeover effect and may delay, deter or prevent a merger or acquisition
of our company by means of a tender offer, a proxy contest or other takeover attempt that a stockholder might consider in its best interest,
including those attempts that might result in a premium over the prevailing market price for the shares of common stock held by stockholders.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Section 203 of the Delaware General Corporation
Law</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are subject to Section 203 of the DGCL, which
prohibits a Delaware corporation from engaging in any business combination with any interested stockholder for a period of three years
after the date that such stockholder became an interested stockholder, with the following exceptions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">before such date, the board of directors of the corporation approved either the business combination or
the transaction that resulted in the stockholder becoming an interested stockholder;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">upon completion of the transaction that resulted in the stockholder becoming an interested stockholder,
the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction began, excluding
for purposes of determining the voting stock outstanding (but not the outstanding voting stock owned by the interested stockholder) those
shares owned (i) by persons who are directors and also officers and (ii) employee stock plans in which employee participants do not have
the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">on or after such date, the business combination is approved by the board of directors and authorized at
an annual or special meeting of the stockholder, and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding
voting stock that is not owned by the interested stockholder.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In general, Section 203 defines business combination
to include the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">any merger or consolidation involving the corporation and the interested stockholder;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">any merger or consolidation involving the corporation and the interested stockholder;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation
of any stock of the corporation to the interested stockholder;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">any transaction involving the corporation that has the effect of increasing the proportionate share of
the stock or any class or series of the corporation beneficially owned by the interested stockholder; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">the receipt by the interested stockholder of the benefit of any loss, advances, guarantees, pledges or
other financial benefits by or through the corporation.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In general, Section 203 defines an &ldquo;interested
stockholder&rdquo; as an entity or person who, together with the person&rsquo;s affiliates and associates, beneficially owns, or within
three years prior to the time of determination of interested stockholder status did own, 15% or more of the outstanding voting stock of
the corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Potential Effects of Authorized but Unissued
Stock</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;<BR>
Pursuant to our Certificate of Incorporation, we have shares of common stock and preferred stock available for future issuance without
stockholder approval. We may utilize these additional shares for a variety of corporate purposes, including future public offerings to
raise additional capital, to facilitate corporate acquisitions or payment as a dividend on the capital stock.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The existence of unissued and unreserved common
stock and preferred stock may enable our Board to issue shares to persons friendly to current management or to issue preferred stock with
terms that could render more difficult or discourage a third-party attempt to obtain control of us by means of a merger, tender offer,
proxy contest or otherwise, thereby protecting the continuity of our management. In addition, our Board has the discretion to determine
designations, rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption
privileges and liquidation preferences of each series of preferred stock, all to the fullest extent permissible under the DGCL and subject
to any limitations set forth in our Certificate of Incorporation. The purpose of authorizing our Board to issue preferred stock and to
determine the rights and preferences applicable to such preferred stock is to eliminate delays associated with a stockholder vote on specific
issuances. The issuance of preferred stock, while providing desirable flexibility in connection with possible financings, acquisitions
and other corporate purposes, could have the effect of making it more difficult for a third-party to acquire, or could discourage a third-party
from acquiring, a majority of our outstanding voting stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Transfer Agent and Registrar</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The transfer agent and registrar for our common
stock is VStock Transfer, LLC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>National Securities Exchange Listing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our common stock is currently listed on Nasdaq
under the symbol &ldquo;KTTA.&rdquo;&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_009"></A>DESCRIPTION OF SECURITIES WE ARE OFFERING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are offering  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock and
Common Warrants to purchase up to  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock. We are also offering Pre-Funded Warrants to those purchasers whose purchase
of shares of common stock in this offering would result in the purchaser, together with its affiliates and certain related parties, beneficially
owning more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding shares of common stock following the consummation
of this offering in lieu of the shares of common stock that would result in such excess ownership. Each Pre-Funded Warrant will be exercisable
for one share of common stock. For each Pre-Funded Warrant we sell, the number of shares of common stock we are offering will be decreased
on a one-for-one basis. No warrant for fractional shares of common stock will be issued, rather warrants will be issued only for whole
shares of common stock. We are also registering the offer and sale of the shares of common stock issuable from time to time upon exercise
of the Pre-Funded Warrants and Common Warrants offered hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The material terms and provisions of our common
stock are described under the caption &ldquo;Description of Capital Stock&rdquo; in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Common Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following is a summary of certain terms and
provisions of the Common Warrants that are being offered hereby is not complete and is subject to, and qualified in its entirety by, the
provisions of the Common Warrant, the form of which will be filed as an exhibit to the registration statement of which this prospectus
forms a part. Prospective investors should carefully review the terms and provisions of the form of Common Warrant for a complete description
of the terms and conditions of the Common Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Duration and Exercise Price</I>. Each Common
Warrant offered hereby will have an exercise price equal to $ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(representing
100% of the price at which a share of common stock and accompanying Common Warrant are sold to the public in this offering). The Common
Warrants will be exercisable beginning on the effective date of Warrant Stockholder Approval; <U>provided</U>, <U>however</U>, that if
the Pricing Conditions are met, the Common Warrants will be exercisable upon issuance (the &ldquo;Initial Exercise Date&rdquo;). The Common
Warrants may be exercised from the Initial Exercise Date until the &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; anniversary
of the issuance date. The exercise price and number of shares of common stock issuable upon exercise is subject to appropriate adjustment
in the event of stock dividends, stock splits, reorganizations or similar events affecting our common stock and the exercise price. The
Common Warrants will be issued separately from the common stock or Pre-Funded Warrants, respectively, and may be transferred separately
immediately thereafter. The Common Warrants will be issued in certificated form only.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We intend to promptly, and in no event later than
90 days after the consummation of this offering, seek stockholder approval for the issuance of shares of common stock issuable upon exercise
of the Common Warrants but we cannot assure you that such stockholder approval will be obtained; <U>provided</U>, <U>however</U>, that,
if and only if the Pricing Conditions are satisfied, then we will not seek Warrant Stockholder Approval. We have agreed with the investors
in this offering that, if we do not obtain stockholder approval for the issuance of the shares of common stock upon exercise of the Common
Warrants at the first stockholder meeting for such purpose after this offering, we will call a stockholder meeting every 90 days thereafter
until the earlier of the date we obtain such approval or the Common Warrants are no longer outstanding, provided, however, that, if and
only if the Pricing Conditions are satisfied, then we will not seek Warrant Stockholder Approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Exercisability</I>. The Common Warrants will
be exercisable, at the option of each holder, in whole or in part, by delivering to us a duly executed exercise notice accompanied by
payment in full for the number of shares of our common stock purchased upon such exercise (except in the case of a cashless exercise as
discussed below). A holder (together with its affiliates) may not exercise any portion of such holder&rsquo;s Common Warrants to the extent
that the holder would own more than 4.99% of the outstanding common stock immediately after exercise, except that upon at least 61 days&rsquo;
prior notice from the holder to us, the holder may increase the amount of ownership of outstanding stock after exercising the holder&rsquo;s
Common Warrants up to 9.99% of the number of shares of our common stock outstanding immediately after giving effect to the exercise, as
such percentage ownership is determined in accordance with the terms of the Common Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Cashless Exercise</I>. If, at the time a holder
exercises its Common Warrants, a registration statement registering the issuance or resale of the shares of common stock underlying the
Common Warrants under the Securities Act is not then effective or available for the issuance of such shares, then in lieu of making the
cash payment otherwise contemplated to be made to us upon such exercise in payment of the aggregate exercise price, the holder may elect
instead to receive upon such exercise (either in whole or in part) the net number of shares of common stock determined according to a
formula set forth in the Common Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Fundamental Transactions</I>. In the event
of any fundamental transaction, as described in the Common Warrants and generally including any merger or consolidation with or into another
entity, sale of all or substantially all of our assets, tender offer or exchange offer, or reclassification of our common stock, then
upon any subsequent exercise of a Common Warrant, the holder will have the right to receive as alternative consideration, for each share
of our common stock that would have been issuable upon such exercise immediately prior to the occurrence of such fundamental transaction,
the number of shares of common stock of the successor or acquiring corporation or of our company, if it is the surviving corporation,
and any additional consideration receivable upon or as a result of such transaction by a holder of the number of shares of our common
stock for which the Common Warrant is exercisable immediately prior to such event. Notwithstanding the foregoing, in the event of a fundamental
transaction, the holders of the Common Warrants have the right to require us or a successor entity to redeem the Common Warrants for cash
in the amount of the Black-Scholes Value (as defined in each Common Warrant) of the remaining unexercised portion of the Common Warrants
on the date of the consummation of such fundamental transaction, concurrently with or within 30 days following the consummation of a fundamental
transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">However, in the event of a fundamental transaction
which is not in our control, including a fundamental transaction not approved by our board of directors, the holders of the Common Warrants
will only be entitled to receive from us or our successor entity, as of the date of consummation of such fundamental transaction the same
type or form of consideration (and in the same proportion), at the Black Scholes Value of the unexercised portion of the Common Warrant
that is being offered and paid to the holders of our common stock in connection with the fundamental transaction, whether that consideration
is in the form of cash, stock or any combination of cash and stock, or whether the holders of our common stock are given the choice to
receive alternative forms of consideration in connection with the fundamental transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Transferability</I>. Subject to applicable
laws, a Common Warrant may be transferred at the option of the holder upon surrender of the Common Warrant to us together with the appropriate
instruments of transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Fractional Shares</I>. No fractional shares
of common stock will be issued upon the exercise of the Common Warrants. Rather, the number of shares of common stock to be issued will,
at our election, either be rounded up to the nearest whole number or we will pay a cash adjustment in respect of such final fraction in
an amount equal to such fraction multiplied by the exercise price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Trading Market</I>. There is no established
trading market for the Common Warrants, and we do not expect an active trading market to develop. We do not intend to apply to list the
Common Warrants on the Nasdaq Capital market or any other securities exchange or other trading market. Without a trading market, the liquidity
of the Common Warrants will be extremely limited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Right as a Stockholder</I>. Except as otherwise
provided in the Common Warrants or by virtue of the holder&rsquo;s ownership of shares of our common stock, such holder of Common Warrants
does not have the rights or privileges of a holder of our common stock, including any voting rights, until such holder exercises such
holder&rsquo;s Common Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Waivers and Amendments</I>. No term of the
Common Warrants may be amended or waived without the written consent of the majority of the holders of the Common Warrants purchased in
this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Pre-Funded Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following summary of certain terms and provisions
of the Pre-Funded Warrants that are being offered hereby is not complete and is subject to, and qualified in its entirety by, the provisions
of the Pre-Funded Warrant, the form of which will be filed as an exhibit to the registration statement of which this prospectus forms
a part. Prospective investors should carefully review the terms and provisions of the form of Pre-Funded Warrant for a complete description
of the terms and conditions of the Pre-Funded Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Duration and Exercise Price</I>. Each Pre-Funded
Warrant offered hereby will have an initial exercise price per share of common stock equal to $0.001. The Pre-Funded Warrants will be
immediately exercisable and will expire when exercised in full. The exercise price and number of shares of common stock issuable upon
exercise is subject to appropriate adjustment in the event of share dividends, share splits, reorganizations or similar events affecting
our shares of common stock and the exercise price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Exercisability</I>. The Pre-Funded Warrants
will be exercisable, at the option of each holder, in whole or in part, by delivering to us a duly executed exercise notice accompanied
by payment in full for the number of shares of common stock purchased upon such exercise (except in the case of a cashless exercise as
discussed below). A holder (together with its affiliates) may not exercise any portion of the Pre-Funded Warrant to the extent that the
holder would own more than 4.99% of the outstanding shares of common stock immediately after exercise, except that upon at least 61 days&rsquo;
prior notice from the holder to us, the holder may increase the amount of beneficial ownership of outstanding shares after exercising
the holder&rsquo;s Pre-Funded Warrants up to 9.99% of the number of our shares of common stock outstanding immediately after giving effect
to the exercise, as such percentage ownership is determined in accordance with the terms of the Pre-Funded Warrants. Purchasers of Pre-Funded
Warrants in this offering may also elect prior to the issuance of the pre- funded warrants to have the initial exercise limitation set
at 9.99% of our outstanding shares of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Cashless Exercise</I>. In lieu of making the
cash payment otherwise contemplated to be made to us upon such exercise in payment of the aggregate exercise price, the holder may elect
instead to receive upon such exercise (either in whole or in part) the number of shares of common stock determined according to a formula
set forth in the Pre-Funded Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Fractional Shares</I>. No fractional shares
of common stock will be issued upon the exercise of the Pre-Funded Warrants. Rather, at our election, the number of shares of common stock
to be issued will be rounded up to the nearest whole number or we will pay a cash adjustment in an amount equal to such fraction multiplied
by the exercise price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Transferability</I>. Subject to applicable
laws, a Pre-Funded Warrant may be transferred at the option of the holder upon surrender of the Pre-Funded Warrants to us together with
the appropriate instruments of transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Trading Market</I>. There is no trading market
available for the Pre-Funded Warrants on any securities exchange or nationally recognized trading system, and we do not expect a trading
market to develop. We do not intend to list the Pre-Funded Warrants on the Nasdaq Capital Market or any other securities exchange or nationally
recognized trading market. Without a trading market, the liquidity of the Pre-Funded Warrants will be extremely limited. The shares of
common stock issuable upon exercise of the Pre-Funded Warrants are currently traded on Nasdaq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Right as a Shareholder</I>. Except as otherwise
provided in the Pre-Funded Warrants or by virtue of such holder&rsquo;s ownership of shares of common stock, the holders of the Pre-Funded
Warrants do not have the rights or privileges of holders of our shares of common stock, including any voting rights, until they exercise
their Pre-Funded Warrants. The Pre-Funded Warrants will provide that holders have the right to participate in distributions or dividends
paid on our shares of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Fundamental Transaction</I>. In the event of
a fundamental transaction, as described in the Pre-Funded Warrants and generally including any reorganization, recapitalization or reclassification
of our shares of common stock, the sale, transfer or other disposition of all or substantially all of our properties or assets, our consolidation
or merger with or into another person, the acquisition of more than 50% of our outstanding securities, or any person or group becoming
the beneficial owner of 50% of the voting power represented by our outstanding shares of securities, the holders of the Pre-Funded Warrants
will be entitled to receive upon exercise of the pre- funded warrants the kind and amount of securities, cash or other property that the
holders would have received had they exercised the Pre-Funded Warrants immediately prior to such fundamental transaction on a net exercise
basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Placement Agent Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, we have agreed to issue to the placement
agent or its designees the placement agent warrants to purchase up to 7% of the aggregate number of shares of common stock sold in this
offering (or common stock equivalent but excluding the shares of common stock underlying the Common Warrants (other than Pre-Funded Warrants)
issued in this offering), at an exercise price equal to 125% of the public offering price per share of common stock and accompanying Common
Warrant to be sold in this offering. The placement agent warrants will be exercisable beginning on the effective date of Warrant Stockholder
Approval; <U>provided</U>, <U>however</U>, that if the Pricing Conditions are met, the placement agent warrants will be exercisable upon
issuance. The placement agent warrants will expire five years from the commencement of sales under this offering. The placement agent
warrants issued in this offering will otherwise have substantially the same terms as the Common Warrants.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_010"></A>PLAN OF DISTRIBUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We engaged&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to act as our exclusive placement agent
to solicit offers to purchase the securities offered by this prospectus on a reasonable best efforts basis. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;is not purchasing or selling
any securities, nor are they required to arrange for the purchase and sale of any specific number or dollar amount of securities, other
than to use their &ldquo;reasonable best efforts&rdquo; to arrange for the sale of the securities by us. Therefore, we may not sell the
entire amount of securities being offered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The terms of this offering are subject to market
conditions and negotiations between us, the placement agent and prospective investors. The placement agent will have no authority to bind
us by virtue of the engagement letter. This is a best efforts offering and there is no minimum amount of proceeds that is a condition
to closing of this offering. Investors purchasing securities offered hereby will have the option to execute a securities purchase agreement
with us. In addition to rights and remedies available to all purchasers in this offering under federal securities and state law, the purchasers
which enter into a securities purchase agreement will also be able to bring claims of breach of contract against us. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;may
engage one or more sub-agents or selected dealers in connection with the offering. The ability to pursue a claim for breach of contract
is material to larger purchasers in this offering as a means to enforce the following covenants uniquely available to them under the securities
purchase agreement: (i) a covenant to not enter into variable rate financings for a period of one year following the closing of the offering,
subject to an exception; and (ii) a covenant to not enter into any equity financings for &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;
&nbsp; &nbsp; &nbsp; days from closing of the offering, subject to certain exceptions.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The nature of the representations, warranties
and covenants in the securities purchase agreements will include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left; width: 0.25in"><FONT STYLE="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify">standard and customary issuer representations and warranties on matters such as due organization, qualification, authorization, no conflict, no governmental filings required, currentness and accuracy of SEC filings, absence of litigation, labor or other compliance issues, environmental, intellectual property and title matters and compliance with various laws such as the Foreign Corrupt Practices Act; and</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 22.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">covenants regarding matters such as registration of the offering of
the warrant shares, the filing of a Current Report on Form 8-K to disclose entering into these securities purchase agreements, the providing
of material nonpublic information, use of proceeds, indemnification of purchasers, reservation and listing of common stock, and prohibitions
on subsequent equity sales for &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; days.</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Delivery of the securities offered hereby is expected
to occur on or about &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2025, subject to satisfaction of certain customary closing conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Fees and Expenses</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table shows the per share and accompanying
Common Warrant, and per Pre-Funded Warrant and accompanying Common Warrant, and total placement agent fees we will pay in connection with
the sale of the securities in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: left">Per share and Common Warrant placement agent cash fees</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Per Pre-Funded Warrant and Common Warrant placement agent cash fees</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Total</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have agreed to pay the placement agent a total
cash fee equal to &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; % of the aggregate gross proceeds raised in the offering and a management
fee equal to &nbsp; &nbsp; &nbsp; &nbsp; % of the gross proceeds raised in this offering. We will reimburse the placement agent a nonaccountable
expense allowance of $&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; , its legal fees and expenses in an
amount up to $&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; and its clearing expense in an amount up to $&nbsp; &nbsp; &nbsp;
&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; in connection with this offering. We estimate the total offering expenses of this offering that
will be payable by us, excluding the placement agent fees and expenses, will be approximately $ million. After deducting the placement
agent fees and our estimated offering expenses, we expect the net proceeds from this offering to be approximately $ million.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Placement Agent Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, we have agreed to issue the placement
agent warrants to the placement agent or its designees to purchase up to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; %
of the aggregate number of shares of common stock sold in this offering (or common stock equivalent but excluding the shares of common
stock underlying the Common Warrants (other than the Pre-Funded Warrants) issued in this offering), at an exercise price equal to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;%
of the public offering price per share and accompanying Common Warrant to be sold in this offering. The placement agent warrants will
be exercisable beginning on the effective date of Warrant Stockholder Approval; <U>provided</U>, <U>however</U>, that if the Pricing Conditions
are met, the placement agent warrants will be exercisable upon issuance. The placement agent warrants will expire five years from the
commencement of sales under this offering.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If at the time of exercise there is no effective
registration statement registering, or the prospectus contained therein is not available for the resale of warrant shares by the holders
of the placement agent warrants, then the placement agent warrants may be exercised, in whole or in part, at such time by means of a &ldquo;cashless
exercise&rdquo; in which the holders shall be entitled to receive a number of warrant shares as calculated in the form of placement agent
warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The placement agent warrants provide for customary
anti-dilution provisions (for share dividends, splits and recapitalizations and the like) consistent with FINRA Rule 5110.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Right of First Refusal</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to consummation of the offering, we have
granted a right of first refusal to the placement agent pursuant to which it has the right to act as the exclusive book-running manager,
underwriter or placement agent, as applicable, if we decide to raise capital through a public offering (including an at-the-market facility)
or private placement or any other capital-raising financing of equity, equity-linked or debt securities (other than a traditional debt
facility or venture debt facility or an equity line of credit) at any time prior to the 12 months following the consummation of this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Tail</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event that any investors that were contacted
by the placement agent or were introduced to us by the placement agent during the term of our engagement agreement with the placement
agent provide any capital to us in a public or private offering or other financing or capital-raising transaction of any kind (each, a
&ldquo;Tail Financing&rdquo;) within twelve months following the termination or expiration of our engagement agreement with the placement
agent, we shall pay the placement agent the cash and warrant compensation provided above on the gross proceeds raised in such Tail Financing
from such investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Determination of Offering Price</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The combined public offering price per share and
accompanying Common Warrant and the combined public offering price per Pre-Funded Warrant and accompanying Common Warrant we are offering
and the exercise prices and other terms of the Pre-Funded Warrants and Common Warrants were negotiated between us and the investors, in
consultation with the placement agent based on the trading of our common stock prior to this offering, among other things. Other factors
considered in determining the public offering prices of the securities we are offering and the exercise prices and other terms of the
Pre-Funded Warrants and Common Warrants include the history and prospects of our company, the stage of development of our business, our
business plans for the future and the extent to which they have been implemented, an assessment of our management, general conditions
of the securities markets at the time of the offering and such other factors as were deemed relevant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Lock-up Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We and each of our officers and directors have
agreed with the placement agent to be subject to a lock-up period of &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;
&nbsp; days following the date of this prospectus. This means that, during the applicable lock-up period, we may not offer for sale, contract
to sell, or sell any shares of our common stock or any securities convertible into, or exercisable or exchangeable for, shares of our
common stock subject to certain customary exception such as issuing stock options to directors, officers, employees and consultants under
our existing plans. The placement agent may, in its sole discretion and without notice, waive the terms of any of these lock-up agreements.
In addition, we have agreed to not issue any shares of common stock or securities exercisable or convertible into shares of common stock
for a period of &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; days following
the closing date of this offering, subject to certain exceptions, and to not issue any securities that are subject to a price reset based
on trading prices of our common stock or upon a specified or contingent event in the future, or enter into an agreement to issue securities
at a future determined price, until the date that is &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; months
following the closing date of the offering.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Transfer Agent and Registrar</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The transfer agent for our common stock is VStock
Transfer, LLC .</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>National Securities Exchange Listing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our common stock and certain of our outstanding
warrants are currently listed on Nasdaq under the symbols &ldquo;KTTA&rdquo; and &ldquo;KTTAW,&rdquo; respectively. On March &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2025, the
closing price per share of our common stock was $  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Indemnification</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have agreed to indemnify the placement agent
against certain liabilities, including certain liabilities arising under the Securities Act and liabilities arising from breaches of representations
and warranties contained in our engagement letter with the placement agent. We have also agreed to contribute to payments that the placement
agent may be required to make for these liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, we will indemnify the purchasers
of securities in this offering against liabilities arising out of or relating to (i) any breach of any of the representations, warranties,
covenants or agreements made by us in the securities purchase agreement or related documents or (ii) any action instituted against a purchaser
by a third party (other than a third party who is affiliated with such purchaser) with respect to the securities purchase agreement or
related documents and the transactions contemplated thereby, subject to certain exceptions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Regulation M</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The placement agent may be deemed to be an underwriter
within the meaning of Section 2(a)(11) of the Securities Act and any fees received by it and any profit realized on the sale of the securities
by it while acting as principal might be deemed to be underwriting discounts or commissions under the Securities Act. The placement agent
will be required to comply with the requirements of the Securities Act and the Exchange Act, including, without limitation, Rule 10b-5
and Regulation M under the Exchange Act. These rules and regulations may limit the timing of purchases and sales of our securities by
the placement agent. Under these rules and regulations, the placement agent may not (i) engage in any stabilization activity in connection
with our securities; and (ii) bid for or purchase any of our securities or attempt to induce any person to purchase any of our securities,
other than as permitted under the Exchange Act, until it has completed its participation in the distribution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Other Relationships</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The placement agent and its affiliates may in
the future engage in investment banking transactions and other commercial dealings in the ordinary course of business with us or our affiliates.
The placement agent may in the future receive customary fees and commissions for these transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, in the ordinary course of their business
activities, the placement agent and its affiliates may make or hold a broad array of investments and actively trade debt and equity securities
(or related derivative securities) for their own account and for the accounts of their customers. Such investments and securities activities
may involve securities and/or instruments of ours or our affiliates. The placement agent and its affiliates may also make investment recommendations
and/or publish or express independent research views in respect of such securities or financial instruments and may hold, or recommend
to clients that they acquire, long and/or short positions in such securities and instruments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except as disclosed in this prospectus, we have
no present arrangements with the placement agent for any further services.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Electronic Distribution</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A prospectus in electronic format may be made
available on a website maintained by the placement agent and the placement agent may distribute prospectuses electronically. Other than
the prospectus in electronic format, the information on these websites is not part of this prospectus or the registration statement of
which this prospectus forms a part, has not been approved and/or endorsed by us or the placement agent and should not be relied upon by
investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B></B></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_011"></A>INFORMATION INCORPORATED BY REFERENCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The SEC allows us to &ldquo;incorporate by reference&rdquo;
information that we file with it into this prospectus, which means that we can disclose important information to you by referring you
to those documents. The information incorporated by reference is an important part of this prospectus. The information incorporated by
reference is considered to be a part of this prospectus, and information that we file later with the SEC will automatically update and
supersede information contained in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We incorporate by reference the following documents
or information that we have filed with the SEC:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            Annual Report on
                                            <A HREF="http://www.sec.gov/Archives/edgar/data/1841330/000101376225001646/ea0230888-10k_pasithea.htm">Form 10-K</A> for the year ended December 31, 2024 filed with the SEC on March 24, 2025.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All other reports and documents filed by us pursuant
to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date that this registration statement becomes effective and after
the date of this prospectus but before the termination of the offering of the securities described in this prospectus shall be deemed
to be incorporated by reference into this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notwithstanding the statements in the preceding
paragraphs, no document, report or exhibit (or portion of any of the foregoing) or any other information that we have &ldquo;furnished&rdquo;
to the SEC pursuant to the Exchange Act shall be incorporated by reference into this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any statement contained in this prospectus or
contained in a document incorporated or deemed to be incorporated by reference into this prospectus will be deemed to be modified or superseded
to the extent that a statement contained in this prospectus or any subsequently filed supplement to this prospectus, or document deemed
to be incorporated by reference into this prospectus, modifies or supersedes such statement. Any statements so modified or superseded
shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You may request a copy of these filings at no
cost, by writing or telephoning us at the following address:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Pasithea Therapeutics Corp.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Atten: Tiago Reis Marques</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Chief Executive Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">1111 Lincoln Road, Suite 500</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Miami Beach, Florida 33139</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Telephone: (786) 977-3380</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You may also access these filings on our website
at www.pasithea.com. You should rely only on the information incorporated by reference or provided in this prospectus. We have not authorized
anyone else to provide different or additional information on our behalf. An offer of these securities is not being made in any jurisdiction
where the offer or sale is not permitted. You should not assume that the information in this prospectus is accurate as of any date other
than the date of those respective documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_012"></A>WHERE YOU CAN FIND MORE INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus is part of a registration statement
we filed with the SEC. This prospectus does not contain all of the information set forth in the registration statement and the exhibits
to the registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For further information with respect to us and
the securities we are offering under this prospectus, we refer you to the registration statement and the exhibits and schedules filed
as a part of the registration statement. You should rely only on the information contained in this prospectus or incorporated by reference
into this prospectus. We have not authorized anyone else to provide you with different information. We are not making an offer of these
securities in any jurisdiction where the offer is not permitted. You should assume that the information contained in this prospectus,
or any document incorporated by reference in this prospectus, is accurate only as of the date of those respective documents, regardless
of the time of delivery of this prospectus or any sale of our securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We file annual, quarterly and current reports,
proxy statements and other information with the SEC. Our SEC filings are available to the public from commercial document retrieval services
and over the Internet at the SEC&rsquo;s website at http://www.sec.gov.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We maintain a website at www.pasithea.com. You
may access our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports
filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act with the SEC free of charge at our website as soon as reasonably
practicable after such material is electronically filed with, or furnished to, the SEC. The information contained in, or that can be accessed
through, our website is not incorporated by reference into, and is not part of, this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_013"></A>LEGAL MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The validity of the securities being offered hereby
and certain other legal matters will be passed upon for us by Lowenstein Sandler LLP, New York, New York.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_014"></A>EXPERTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The audited annual consolidated financial statements
of Pasithea Therapeutics Corp. incorporated by reference in this prospectus and elsewhere in the registration statement have been incorporated
by reference in reliance upon the report of Marcum LLP, independent registered public accounting firm, which includes an explanatory paragraph
as to our ability to continue as a going concern, upon the authority of said firm as experts in accounting and auditing. The 2024 and
2023 audited annual consolidated financial statements of Pasithea Therapeutics Corp. as of and for the years ended December 31, 2024 and
2023, have been audited by Marcum LLP, independent registered public accounting firm.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="padding: 0.75pt"></TD></TR>
  <TR>
    <TD STYLE="padding: 0.75pt"></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_002.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Up to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares of Common
Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Pre-Funded Warrants to Purchase up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares
of Common Stock </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Common Warrants to Purchase up to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shares of
Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Shares of Common Stock underlying Pre-Funded
Warrants and Common Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PRELIMINARY PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">The date of this prospectus is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="padding: 0.75pt"></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PART II</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05pt; text-align: center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 13. Other Expenses of Issuance and Distribution.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth the costs and expenses,
other than placement agent fees and commissions, payable by us in connection with the sale and distribution of the securities being registered.
All of the amounts shown are estimates, except for the SEC registration fee and the FINRA filing fee:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount <BR>
to be paid</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: left">SEC registration fee</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">FINRA filing fee</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Legal fees and expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Accounting fees and expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">Miscellaneous</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">Total expenses</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; padding-bottom: 4pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">*</TD><TD STYLE="text-align: justify">To be filed by amendment.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 14. Indemnification of Directors and Officers.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section 102 of the DGCL permits a corporation
to eliminate the personal liability of directors and officers of a corporation to the corporation or its stockholders for monetary damages
for a breach of fiduciary duty as a director or officer, except where the director breached his duty of loyalty, failed to act in good
faith, engaged in intentional misconduct or knowingly violated a law, obtained an improper personal benefit, in the case of a director,
authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law, or in the case of an officer,
a breach of fiduciary duty in any action by or in the right of the corporation. Our Certificate of Incorporation provides that no director
or officer shall be personally liable to it or its stockholders for monetary damages for any breach of fiduciary duty as a director or
officer to the fullest extent permitted by the DGCL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section 145 of the DGCL provides that a corporation
has the power to indemnify a director, officer, employee, or agent of the corporation, or a person serving at the request of the corporation
for another corporation, partnership, joint venture, trust or other enterprise in related capacities against expenses (including attorneys&rsquo;
fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with an action, suit
or proceeding to which he was or is a party or is threatened to be made a party to any threatened, ending or completed action, suit or
proceeding by reason of such position, if such person acted in good faith and in a manner he reasonably believed to be in or not opposed
to the best interests of the corporation, and, in any criminal action or proceeding, had no reasonable cause to believe his conduct was
unlawful, except that, in the case of actions brought by or in the right of the corporation, no indemnification shall be made with respect
to any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the
extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in view of all
of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery
or such other court shall deem proper.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Certificate of Incorporation and Bylaws provide
that we will indemnify each person who was or is a party to or is threatened to be made a party to any threatened, pending or completed
action, suit or proceeding, whether civil, criminal, administrative or investigative by reason of the fact that the person is or was a
director, officer, employee or agent of us, or is or was serving at the request of us as a director, officer, employee or agent of another
corporation, partnership, joint venture, trust or other enterprise (all such persons being referred to as an &ldquo;Indemnitee&rdquo;),
or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys&rsquo; fees),
judgments, fines and amounts paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding and
any appeal therefrom, if such Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to,
our best interests, and, with respect to any criminal action or proceeding, he or she had no reasonable cause to believe his or her conduct
was unlawful. Our Certificate of Incorporation and Bylaws provide that we will indemnify any Indemnitee who was or is a party to an action
or suit by or in the right of us to procure a judgment in our favor by reason of the fact that the Indemnitee is or was a director or
officer, or is or was serving at our request as a director, officer, partner, employee or trustee of, or in a similar capacity with, another
corporation, partnership, joint venture, trust or other enterprise, or by reason of any action alleged to have been taken or omitted in
such capacity, against all expenses (including attorneys&rsquo; fees) and, to the extent permitted by law, amounts paid in settlement
actually and reasonably incurred in connection with such action, suit or proceeding, and any appeal therefrom, if the Indemnitee acted
in good faith and in a manner he or she reasonably believed to be in, or not opposed to, our best interests, except that no indemnification
shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to us, unless a
court determines that, despite such adjudication but in view of all of the circumstances, he or she is entitled to indemnification of
such expenses. Notwithstanding the foregoing, to the extent that any Indemnitee has been successful, on the merits or otherwise, he or
she will be indemnified by us against all expenses (including attorneys&rsquo; fees) actually and reasonably incurred in connection therewith.
Expenses must be advanced to an Indemnitee under certain circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 30; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have entered into indemnification agreements
with each of our directors and officers. These indemnification agreements require us, among other things, to indemnify our directors and
officers for some expenses, including attorneys&rsquo; fees, judgments, fines and settlement amounts incurred by a director or officer
in any action or proceeding arising out of his or her service as one of our directors or officers, or any other company or enterprise
to which the person provides services at our request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We maintain a general liability insurance policy
that covers certain liabilities of our directors and officers arising out of claims based on acts or omissions in their capacities as
directors or officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In any underwriting agreement we enter into in
connection with the sale of our common stock, the underwriters will agree to indemnify, under certain conditions, us, our officers and
directors, and persons who control us within the meaning of the Securities Act, against certain liabilities.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 15. Recent Sales of Unregistered
Securities. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>September 2024 Private Placement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 26, 2024, we entered into a
securities purchase agreement with an institutional investor for the issuance and sale in the Private Placement of (i) pre-funded warrants
to purchase up to 1,219,513 shares of our common stock at an exercise price of $0.001 per share, (ii) Series A warrants to purchase up
to 1,219,513 shares of our common stock at an exercise price of $3.85 per share, and (iii) Series B warrants to purchase up to 1,219,513
shares of our common stock with an exercise price of $3.85 per share. The pre-funded warrants were exercisable immediately upon on issuance
and expire when exercised in full. The Series A warrants were exercisable immediately upon issuance and have a term of exercise equal
to five years from the date of issuance. The Series B warrants were exercisable immediately upon issuance and have a term of exercise
equal to 18 months from the date of issuance. The combined purchase price per pre-funded warrant and accompanying warrants was $4.099.
The Private Placement closed on September 30, 2024. &nbsp;The net proceeds from the Private Placement were approximately $4.5 million,
after deducting placement agent fees and estimated offering expenses payable by us. We intend to use the net proceeds received from the
Private Placement for working capital and general corporate purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">H.C. Wainwright &amp; Co., LLC (&ldquo;H.C. Wainwright&rdquo;)
acted as our exclusive placement agent in connection with the Private Placement, pursuant to that certain engagement letter, dated as
of September 6, 2024, as amended, between us and H.C. Wainwright. Pursuant to the engagement letter, we paid H.C. Wainwright (i) a total
cash fee equal to 7.0% of the aggregate gross proceeds of the Private Placement, (ii) a management fee of 1.0% of the aggregate gross
proceeds of the Private Placement and (iii) $50,000 for non-accountable expenses. In addition, we issued to H.C. Wainwright or its designees
placement agent warrants to purchase up to an aggregate of 85,366 shares of common stock at an exercise price equal to $5.125 per share.
The placement agent warrants have substantially the same terms as the Series A warrants and Series B warrants, are exercisable immediately
upon issuance and have a term of exercise equal to five years from the date of issuance. In addition, pursuant to the engagement letter,
upon any exercise of the Series A warrants and Series B warrants for cash, we agreed to (i) pay H.C. Wainwright a total cash fee equal
to 7.0% of the aggregate gross proceeds from such exercise and (ii) issue to H.C. Wainwright or its designees additional placement agent
warrants to purchase the number of shares of common stock equal to 7.0% of the aggregate number of such shares of common stock underlying
the Series A warrants and Series B warrants that have been exercised (or up to an aggregate of 170,732 shares of common stock, assuming
full exercise of the Series A warrants and Series B warrants for cash).&nbsp;Any additional placement agent warrants will have the same
terms as the placement agent warrants.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Neither the issuance of the pre-funded warrants,
the Series A warrants, the Series B warrants, the placement agent warrants nor the shares of common stock issuable upon exercise thereof,
as applicable, were registered under the Securities Act or any state securities laws. The pre-funded warrants, the Series A warrants,
the Series B warrants and the placement agent warrants were, and the shares of common stock issuable upon the exercise thereof will be,
issued in reliance on the exemptions from registration provided by Section 4(a)(2) under the Securities Act and/or Regulation D promulgated
thereunder. The additional placement agent warrants and the shares of common stock issuable upon the exercise thereof will be issued in
reliance on the exemptions from registration provided by Section 4(a)(2) under the Securities Act and/or Regulation D promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>October 2022 AlloMek Acquisition</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 11, 2022, we entered into a Membership
Interest Purchase Agreement, dated October 11, 2022 (the &ldquo;AlloMek Agreement&rdquo;), by and among us, AlloMek Therapeutics, LLC
(&ldquo;AlloMek&rdquo;), the persons listed on Schedule 1.1 thereto (the &ldquo;AlloMek Sellers&rdquo;), and Uday Khire, as the representative
of the AlloMek Sellers, pursuant to which the AlloMek Sellers sold all of the issued and outstanding equity of AlloMek to the us. The
AlloMek Sellers were the sole title and beneficial owners of 100% of the equity interests of AlloMek. In consideration of the sale of
the equity of AlloMek, the AlloMek Sellers received (i) an aggregate of 135,000 shares of our common stock, (ii) an aggregate of 50,000
warrants to purchase shares of our common stock at an exercise price of $37.60 per share, which may be exercised on a cashless basis,
for a period of five years from the date of issuance, (iii) a cash payment in the amount of $1,050,000, (iv) the right to certain milestone
payments in an amount up to $5,000,000, and (v) the right to contingent earn-out payments ranging from 3% to 5% of net sales of the Drug
(as defined in the AlloMek Agreement) depending on the amount of such net sales in the applicable measurement period. Closing of the transactions
contemplated in the AlloMek Agreement occurred on October 11, 2022. The common stock and warrants were issued to the AlloMek Sellers without
registration under the Securities Act, or any state securities laws, in a transaction not involving a public offering. We relied on the
exclusion from the registration requirements of the Securities Act afforded by Section 4(a)(2) thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>June 2022 Alpha-5 Acquisition</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 21, 2022, we entered into a Membership
Interest Purchase Agreement (the &ldquo;Alpha-5 Agreement&rdquo;) with Lawrence Steinman, who is the Executive Chairman of our board of
directors and one of our co-founders and as such is a related party, and PD Joint Holdings, LLC Series 2016-A (the &ldquo;Alpha-5 Sellers&rdquo;),
pursuant to which the Alpha-5 Sellers sold all of the issued and outstanding equity of Alpha-5 integrin, LLC (&ldquo;Alpha-5&rdquo;) to
us. The Alpha-5 Sellers were the sole title and beneficial owners of 100% of the equity interests of Alpha-5. In consideration of the
equity of Alpha-5, the Sellers received (i) an aggregate of 163,043 shares of our common stock, (ii) an aggregate of 50,000 warrants to
purchase shares of our common stock at an exercise price of $37.60 per share, which may be exercised on a cashless basis, for a period
of five years from the date of issuance, and (iii) the right to contingent earn-out payments of an aggregate of 2% to 4% of net sales
generated from the sale of a drug in development by Alpha-5. The transaction closed on June 21, 2022. The warrants and shares were sold
to the Alpha-5 Sellers without registration under the Securities Act, or any state securities laws in a transaction not involving a public
offering and the Alpha-5 Sellers represented they are an accredited investor. We relied on the exclusion from the registration requirements
of the Securities Act afforded by Section 4(a)(2).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 16. Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify; width: 9%"><B>Exhibit No.</B></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: justify; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify; width: 90%"><B>Description of Document</B></TD></TR>
  <TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; text-align: justify">2.1</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1841330/000121390022048085/f10q0622ex2-01_pasithea.htm">Membership Interest Purchase Agreement entered into June 21, 2022, by and among Pasithea Therapeutics Corp., Alpha-5 integrin, LLC, and certain Sellers (as defined in the agreement) (incorporated by reference to Exhibit 2.01 of the Company&rsquo;s Form 10-Q, filed with the SEC on August 15, 2022).</A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; text-align: justify">2.2</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1841330/000121390022063416/ea167014ex2-1_pasithea.htm">Membership Interest Purchase Agreement dated October 11, 2022 by and among Pasithea Therapeutics Corp., AlloMek Therapeutics, LLC, the Persons listed on Schedule 1.1 thereto, and Uday Khire, not individually but in his capacity as the representative of the Persons listed on Schedule 1.1 thereto (incorporated by reference to Exhibit 2.1 of the Company&rsquo;s Form 8-K, filed with the SEC on October 12, 2022).</A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; text-align: justify">2.3</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1841330/000121390022063416/ea167014ex2-2_pasithea.htm">Form of Lock-up Agreement dated October 11, 2022 (incorporated by reference to Exhibit 2.2 of the Company&rsquo;s Form 8-K, filed with the SEC on October 12, 2022).</A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; text-align: justify">3.1</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1841330/000121390024000296/ea190803ex3-1_pasithea.htm">Second Amended and Restated Certificate of Incorporation of Pasithea Therapeutics Corp., dated December 29, 2023. (incorporated by reference to Exhibit 3.1 of the Company&rsquo;s Form 8-K, filed with the SEC on January 2, 2024).</A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; text-align: justify">3.2</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1841330/000121390024000296/ea190803ex3-4_pasithea.htm">Certificate of Amendment to the Second Amended and Restated Certificate of Incorporation of Pasithea Therapeutics Corp., dated December 29, 2023 (incorporated by reference to Exhibit 3.4 of the Company&rsquo;s Form 8-K, filed with the SEC on January 2, 2024).</A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; text-align: justify">3.3</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1841330/000121390024000296/ea190803ex3-2_pasithea.htm">Second Amended and Restated Bylaws of Pasithea Therapeutics Corp., dated December 29, 2023, (incorporated by reference to Exhibit 3.2 of the Company&rsquo;s Form 8-K, filed with the SEC on January 2, 2024).</A></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; text-align: justify">4.1</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1841330/000121390021040632/ea144160ex4-1_pasitheathera.htm">Specimen Common Stock Certificate evidencing the shares of Common Stock (incorporated by reference to Exhibit 4.1 of the Company&rsquo;s Form S-1 (File No. 333-255205), filed with the SEC on April 13, 2021, as amended).</A></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="text-align: justify; text-indent: 22.5pt">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; text-align: justify">4.2</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1841330/000121390021045117/ea145577ex4-2_pasitheathera.htm">Form of Warrant Agent Agreement, including Form of Warrant Certificate (incorporated by reference to Exhibit 4.2 of the Company&rsquo;s Form S-1 (File No. 333-255205), filed with the SEC on April 13, 2021, as amended).</A></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="text-align: justify; text-indent: 22.5pt">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; text-align: justify">4.3</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1841330/000121390021040632/ea144160ex4-3_pasitheathera.htm">Form of Representative Warrant (incorporated by reference to Exhibit 4.3 of the Company&rsquo;s Form S-1 (File No. 333-255205), filed with the SEC on April 13, 2021, as amended).</A></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="text-align: justify; text-indent: 22.5pt">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; text-align: justify">4.4</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1841330/000121390021062398/ea151423ex10-3_pasithea.htm">Form of Warrants issued in private placement (incorporated by reference to Exhibit 10.3 of the Company&rsquo;s Current Report on Form 8-K filed with the SEC on November 29, 2021).</A></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="text-align: justify; text-indent: 22.5pt">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; text-align: justify">4.5</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1841330/000121390023039106/ea178450ex4-3_pasitheathe.htm">Form of Warrants Issued in acquisition of AlloMek Therapeutics, LLC (incorporated by reference to Exhibit 4.3 of the Company&rsquo;s Form S-3 (File No. 333-271896) filed with the SEC on May 12, 2023).</A></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="text-align: justify; text-indent: 22.5pt">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; text-align: justify">4.6</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1841330/000121390023039106/ea178450ex4-4_pasitheathe.htm">Form of Warrant Issued in acquisition of Alpha-5 integrin, LLC (incorporated by reference to Exhibit 4.4 of the Company&rsquo;s Form S-3 (File No. 333-271896) filed with the SEC on May 12, 2023).</A></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="text-align: justify; text-indent: 22.5pt">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; text-align: justify">4.7</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1841330/000121390024083408/ea021586301ex4-1_pasithea.htm">Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 of the Company&rsquo;s Current Report on Form 8-K filed with the SEC on September 30, 2024).</A></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; text-align: justify; width: 9%">4.8</TD>
    <TD STYLE="text-align: justify; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; width: 90%"><A HREF="http://www.sec.gov/Archives/edgar/data/1841330/000121390024083408/ea021586301ex4-2_pasithea.htm">Form of Warrant (incorporated by reference to Exhibit 4.2 of the Company&rsquo;s Current Report on Form 8-K filed with the SEC on September 30, 2024).</A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; text-align: justify">4.9</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1841330/000121390024083408/ea021586301ex4-3_pasithea.htm">Form of Placement Agent Warrant (incorporated by reference to Exhibit 4.3 of the Company&rsquo;s Current Report on Form 8-K filed with the SEC on September 30, 2024).</A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; text-align: justify">4.10</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1841330/000121390024027508/ea020041501ex4-7_pasithea.htm">Description of Securities (incorporated by reference to Exhibit 4.7 of the Company&rsquo;s Annual Report on Form 10-K filed with the Commission on March 29, 2024).</A></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; text-align: justify">4.11</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Form of Pre-Funded Warrant issued in this Offering.**</TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="text-align: justify; text-indent: 22.5pt">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; text-align: justify">4.12</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Form of Common Warrant issued in this Offering.**</TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="text-align: justify">4.13</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Form of Placement Agent Warrant issued in this Offering. **</TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="text-align: justify; text-indent: 22.5pt">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; text-align: justify">5.1</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Opinion of Lowenstein Sandler LLP.**</TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="text-align: justify; text-indent: 22.5pt">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; text-align: justify">10.1</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1841330/000121390021040632/ea144160ex10-7_pasitheathera.htm">2021 Incentive Plan (incorporated by reference to Exhibit 10.7 of the Company&rsquo;s Form S-1 (File No. 333-255205), filed with the SEC on April 13, 2021, as amended).</A></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="text-align: justify; text-indent: 22.5pt">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; text-align: justify">10.2</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1841330/000121390021040632/ea144160ex10-8_pasitheathera.htm">Form of Indemnification Agreement for Officers and Directors (incorporated by reference to Exhibit 10.8 of the Company&rsquo;s Form S-1 (File No. 333-255205), filed with the SEC on April 13, 2021, as amended).</A> &dagger;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; text-align: justify">10.3</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1841330/000121390021062398/ea151423ex10-2_pasithea.htm">Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.2 of the Company&rsquo;s Form 8-K, filed with the SEC on November 29, 2021).</A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; text-align: justify">10.4</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1841330/000121390021062398/ea151423ex10-4_pasithea.htm">Form of Registration Rights Agreement (incorporated by reference to Exhibit 10.4 of the Company&rsquo;s Form 8-K, filed with the SEC on November 29, 2021).</A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; text-align: justify">10.5</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1841330/000121390022025941/f10k2021a1ex10-15_pasithea.htm">Executive Employment Agreement, dated as of January 1, 2022, between Pasithea Therapeutics Corp. and Dr. Tiago Reis Marques (incorporated by reference to Exhibit 10.15 of the Company&rsquo;s Form 10-K/A, filed with the SEC on May 12, 2022).</A> &dagger;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; text-align: justify">10.6</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1841330/000121390022025941/f10k2021a1ex10-16_pasithea.htm">Stock Option Agreement, dated December 20, 2021, between Pasithea Therapeutics Corp. and Dr. Tiago Reis Marques (incorporated by reference to Exhibit 10.16 of the Company&rsquo;s Form 10-K/A, filed with the SEC on May 12, 2022).</A> &dagger;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; text-align: justify">10.7</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1841330/000121390022072281/f10q0922ex10-1_pasithea.htm">Employment Agreement with Daniel Schneiderman (incorporated by reference to Exhibit 10.1 of the Company&rsquo;s Form 10-Q, filed with the SEC on November 14, 2022).</A> &dagger;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; text-align: justify">10.8</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1841330/000121390022079827/ea170172ex10-1_pasithea.htm">Settlement and Cooperation Agreement dated December 9, 2022, by and between Pasithea Therapeutics Corp. and Camac Fund, LP and its affiliates (incorporated by reference to Exhibit 10.1 of the Company&rsquo;s Form 8-K, filed with the SEC on December 14, 2022).</A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; text-align: justify">10.9</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1841330/000121390023097013/ea190360ex10-1_pasithea.htm">Pasithea Therapeutics Corp. 2023 Stock Incentive Plan (incorporated by reference to Exhibit 10.1 of the Company&rsquo;s Form 8-K filed with the SEC on December 19, 2023).</A> &dagger;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; text-align: justify">10.10</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/0001841330/000121390024027508/ea020041501ex10-20_pasithea.htm">Consulting Agreement between Pasithea Therapeutics Corp. and Dr. Lawrence Steinman, dated November 13, 2023 (incorporated by reference to Exhibit 10.20 of the Company&rsquo;s Form 10-K filed with the SEC on March 29, 2024).</A> &dagger;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; text-align: justify">10.11</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1841330/000121390024083408/ea021586301ex10-1_pasithea.htm">Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 of the Company&rsquo;s Current Report on Form 8-K filed with the SEC on September 30, 2024).</A></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; text-align: justify; width: 9%">10.12</TD>
    <TD STYLE="text-align: justify; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; width: 90%"><A HREF="http://www.sec.gov/Archives/edgar/data/1841330/000121390024083408/ea021586301ex10-2_pasithea.htm">Form of Registration Rights Agreement (incorporated by reference to Exhibit 10.2 of the Company&rsquo;s Current Report on Form 8-K filed with the SEC on September 30, 2024).</A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; text-align: justify">10.13</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1841330/000121390024102903/ea022254701ex1-1_pasithea.htm">ATM Agreement, dated November 26, 2024, by and between Pasithea Therapeutics Corp. and H.C. Wainwright &amp; Co., LLC (incorporated by reference to Exhibit 1.1 of the Company&rsquo;s Current Report on Form 8-K filed with the SEC on November 26, 2024).</A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; text-align: justify">10.14</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Form of Securities Purchase Agreement to be entered into in this Offering. **</TD></TR>
  <TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; text-align: justify">21.1</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1841330/000101376225001646/ea023088801ex21-1_pasithea.htm">Subsidiaries of the Registrant (incorporated by reference to Exhibit 21.1 of the Company&rsquo;s Annual Report on Form 10-K filed with the Commission on March 24, 2025).</A></TD></TR>
  <TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; text-align: justify">23.1</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Consent of Independent Registered Public Accounting Firm (Marcum LLP).*</TD></TR>
  <TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; text-align: justify">23.2</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Consent of Lowenstein Sandler LLP (included as part of Exhibit 5.1).**</TD></TR>
  <TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; text-align: justify">24.1</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><A HREF="#toc">Power of Attorney (included in the signature page to this registration statement).*</A></TD></TR>
  <TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; text-align: justify">107</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Filing Fee Table. **</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="text-align: left; width: 0.25in">*</TD>
    <TD STYLE="text-align: left">Filed herewith.</TD></TR>
  <TR>
    <TD STYLE="text-align: left">**</TD>
    <TD STYLE="text-align: left">To be filed by amendment.</TD></TR>
  <TR>
    <TD STYLE="text-align: left">&dagger;</TD>
    <TD STYLE="text-align: left">Indicates a management contract or compensation plan, contract or arrangement.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 17. Undertakings.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned registrant hereby undertakes</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(a) To file, during any period in which offers
or sales are being made, a post-effective amendment to this registration statement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(i) To include any prospectus required
by Section 10(a)(3) of the Securities Act;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(ii) To reflect in the prospectus any
facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which,
individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding
the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed
that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the
form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more
than 20 percent change in the maximum aggregate offering price set forth in the &ldquo;Calculation of Registration Fee&rdquo; table in
the effective registration statement; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(iii) To include any material information
with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information
in the registration statement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(b) that, for the purpose of determining any liability
under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities
offered therein, and the offering of such securities at that time shall be deemed to be the initial&nbsp;<I>bona fide</I>&nbsp;offering
thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(c) to remove from registration by means of a
post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(d) that, for the purpose of determining liability
under the Securities Act of 1933 to any purchaser, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating
to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall
be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness.&nbsp;<I>Provided,
however</I>, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a
document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration
statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was
made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately
prior to such date of first use.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(e) that, for the purpose of determining liability
of the registrant under the Securities Act to any purchaser in the initial distribution of the securities, the undersigned registrant
hereby undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless
of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means
of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or
sell such securities to such purchaser:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(i) Any preliminary prospectus or prospectus
of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424 (&sect; 230.424 of this chapter);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(ii) Any free writing prospectus relating
to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(iii) The portion of any other free
writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided
by or on behalf of the undersigned registrant; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(iv) Any other communication that is
an offer in the offering made by the undersigned registrant to the purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(f) Insofar as indemnification for liabilities
arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the Registrant pursuant to
the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the SEC such indemnification is against
public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities
(other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant
in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection
with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling
precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed
in the Act and will be governed by the final adjudication of such issue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(g) That:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(1) For purposes of determining any
liability under the Securities Act of 1933, the information omitted from the form of prospectus filed as part of this registration statement
in reliance upon Rule 430A and contained in a form of prospectus filed by the Registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under
the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(2) For the purpose of determining any
liability under the Securities Act of 1933, each post-effective amendment that contains a form of prospectus shall be deemed to be a new
registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to
be the initial bona fide offering thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 33.75pt">Pursuant to the requirements
of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned,
thereunto duly authorized in the City of Miami Beach, State of Florida, on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left"><B>PASITHEA THERAPEUTICS CORP.</B></TD>
    </TR>
  <TR>
    <TD STYLE="text-align: left; width: 60%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 4%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 36%">&nbsp;</TD>
    </TR>
  <TR>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    </TR>
  <TR>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">Dr. Tiago Reis Marques </TD>
    </TR>
  <TR>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">Chief Executive Officer and Director</TD>
    </TR>
  <TR>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">(Principal Executive Officer)</TD>
    </TR>
  <TR>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    </TR>
  <TR>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">By: </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    </TR>
  <TR>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">Daniel Schneiderman </TD>
    </TR>
  <TR>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">Chief Financial Officer</TD>
    </TR>
  <TR>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">(Principal Financial and Accounting Officer)</TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="toc"></A>POWER OF ATTORNEY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We, the undersigned officers and directors of
Pasithea Therapeutics Corp., hereby severally constitute and appoint Dr. Tiago Reis Marques and Daniel Schneiderman, and each of them
singly (with full power to each of them to act alone), to sign any and all amendments (including post-effective amendments) to this registration
statement (or any other registration statement for the same offering that is to be effective upon filing pursuant to Rule 462(b) under
the Securities Act of 1933), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities
and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform
each and every act and thing requisite or necessary to be done in and about the premises, as full to all intents and purposes as he might
or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or their or his substitute
or substitutes, may lawfully do or cause to be done by virtue hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Act of 1933, this registration statement has been signed by the following persons on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2025 in the capacities indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: top; text-align: center; width: 32%"><B>Signature</B></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: top; text-align: center; width: 32%"><B>Title</B></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: top; text-align: center; width: 32%"><B>Date</B></TD></TR>
  <TR>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>Chief Executive Officer and Director</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: left">Dr. Tiago Reis Marques</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">(Principal Executive Officer)</P></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>Chief Financial Officer</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="text-align: left">Daniel Schneiderman</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">(Principal Financial and Accounting Officer)</P></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>Director</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="text-align: left">Prof. Lawrence Steinman</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>Director</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="text-align: left">Simon Dumesnil</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>Director</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="text-align: left">Dr. Emer Leahy</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>Director</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="text-align: left">Alfred Novak</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 38; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !% 4X# 2(  A$! Q$!_\0
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MK>+#H0\:^-FEF^&OV\W*_#0_#3^SD\%QH=)/_"-M/]M-L@!U]9)-2Q&W4_\
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MJ^KZ!;7NFV&L>&8;+3E>\=9O#]HX2\']>U]_P2N_X)Q:EX03P-=?L6?L\?\
M".Q6DEE%';?#C0['5X8I0%>6'Q/906_B>*^;&XZG'K"ZCO+2"Z$C,Q_AH_X+
M7?L#?!K_ ()\_M3>&/A_\#O%&N7_ ()^*'P\?XG6/@7Q)/)JNJ_#*)O$6H>'
M%T6#Q-/*]YK^A:G=:9?W>AMJJ'6-,@M9K&]O=3C6VO'Z\KS7A?B;&T\'+)(4
M,52;Q.'<\-A%&<<.XU)*53!PI+EY>5SH8BG5HU8MPO>R<RC4IJ_/=/1ZOKZ_
MFK,^ZO\ @CS_ ,%$O^"BG[5G_!0WX&?"'XF_M3>//&'PTDM?'WC3Q[X9O='\
M%V]EK6@>#O!VI74-E>W&G>&+.^AMI?$-[H"2-;74#NSQPE]DK _T5?\ !7'_
M (*M>%?^":OPU\-VF@^'M/\ B)^T-\58]4'PO\!ZG=W%KX?TS2](:W@UCQ[X
MYGL674(_#.E7-Y;6=GIEA);:CXEU61M.L;RRAM=1U"R_GB_X-9_A>VO_ +6'
M[17Q<N+1);+X<? _1O"%A=NF6M=;^(_C"&]<0N5(5I-'\$WJ3!&#[)(]_P K
M*#YU_P '/'A3QEI/[?/P[\7:W'?2>#O&/[._ANP\"WLJ2'34N?"GBSQ2GB_1
M[.8_N1>VUWK6DZK?6R$3>3JUE.ZF-HVK@QN5Y7F'&]#+)8?#T,)A<OC5JX?#
MTZ>'AB:\:<L3[.:HQIMW56FZEGSRI4G!2C&3<:4I1I.5VVY6N];+:^M_^'/S
ME^,__!83_@I%\9-9O-=\7?M?_$KP79W-V;BW\.?"K5;;X2>$],4.SV]K96OA
M5+#4)HK9#Y22:MK&IW=PB[KVXNIBTIZOX%_\%L?^"E?P3UFSUC1/VI?$_P 5
M=&ADC^U>$_C4FG_%#PWJ5NA!:T:]O4M_$^G+)C#7.C>)+"\7.5FP65O8O^"+
M7[7W["7[*?Q2^(J?ML_!K1_%MO\ $*/PS9> OC/K7@6Q^)FG_"6+3_ML.NZ1
MJ7A2YT_5+^PTCQ+/=V.I7?BS0-.OM1L#I9L[^V&F2?:;?^O#Q_\ \$WO^"3?
M_!2#P3X?^)OAKX<_"#Q-I%[/I%_IGQ6_9OU/2/!>I:A9V5S#?3>']:U'P&+:
MSOK34H ^FZ[H_B/39=4M[2XN;>,Z9?*D\/K9QF639-76 QW"_P#PFN,8PQU+
M X&>&J<U-2<:<51C4YH2]R2EBZ5?F3G&,HVDYC&4E=5/>[7=_P _TL>R?\$N
MOVX/&W_!0']ES1?CYXX^!NL_!2_N]9U#P_;F6_CU+P9\0ET;R[:^\:_#6[N'
MBUV3PA-JBWNEQC7+&&6'4=/OK6TU#6K:W&I2_P EO_!3W_@K[^W;X&_;]_:@
M^'?P(_:3\7_#KX6?#3X@Q_#SP[X3T72?!UU865WX2\/Z-IGB6ZCN=4\/:E>S
M/J/B>/5[QVENW5?,6.-(U38/[O\ 2M(\(?"[P-9:)X>TC2O"?@7P!X9BLM)T
M31K.'3]'\/\ AKPWIH2VL-/LK=$AM;+3].M%B@AB0*D<0 %?Y*?QD^(-Y\3_
M (L_%[XK:I.;J]^(?Q,^(?C^YN&)8RIXF\5:QK=N"V-S+#975O;HQ&YHX4+?
M,37S_!&"P&99IG6+>7T(X*$*<,+@Z\5BH4/K&(E.,5*O&HI3C1H6<GK'GE&#
MY$KW5;C&*YG?JUI>R\K=7_3/O9_^"U?_  4_B8J_[:?CU' &Y'TGX=*RGG&4
M;PD"N1@X(!((/0BODC]H;]JS]H3]KCQ+H'C?]HOXK:Y\6_$OAG09/#'AW6M;
M@T:V;2_#\NH3:G-IUG#H6G:99&*;49I;J:9H)+B638LDS)%&J?Z /_!,#]@3
M]F;2_P#@GU^R2WQ,_9R^"WC+QWKWP8\+>-?$OB;QC\+_  9K_B75K_Q[ _C-
M)M5U;5=&NM0NI8K/7+6UA%Q.Q@MK>&!5C6,(O\(O_!0S6_!?B#]NS]K>]^'&
MA:#X8\ 67QV\;^&/"'A_POH^G:!X=TS1?!%Y'X*CBTC1])@MM-LK2YN_#UWJ
M %I D5Q+>2W>"T[,?J\AS/*,PS3,,-@,EH8.IEOM8O&TZ6#A[1?6:F$M3]C0
MA5@JOLISM*;]R/++F9E.,HQ3<F^:VEWVOK=V.!_9V_;#_:*_9 U?Q5K?[.7Q
M?U3X0ZWXXTW3-)\5ZAHUEX:N[S6M+T:ZNKW2[.=O$&DZJ88+2[O+N>,6@@+O
M,_FM(, ?T%?\$4/^"AG_  4!_:[_ ."A/PT^%WQ6_:H\;>.OA?H_@KXF?$'Q
MSX4N=+\$1V&M6'A[P\NDZ-:7\^E^&[._@MQXH\2:'>*UM=V[O+9K$S/$TL;_
M *@_\$#?V)/@)XB_X)O?#GXA_&3X#_"/XB^*OBCX[^)WC:RU[QW\.O"OBG78
M_#/_  E5UX8\/Z<-2UW2KZ]CL;>U\-O/:VD<PM4^UR30QKY[$_NU\.OV:_V>
M/A!KEQXF^%/P,^$?PV\1W>G2:1=:]X%^'?A/PKK-QI4T\-S-ILVI:)I-E>26
M,MQ;6\\MHTQ@DE@AD="T2%?F.).*,IG4S? +):=7'16(P,<RG'!3:J02H*LG
M*A*NE2_>1@E4YHN*<9*R:TA3E[KYM-'RZ^MM['\,7_!R]\3YO&W_  48TSP&
MLB-I_P &/@)X#T")48';K'C?4_$'C?5A(HR!(NGWOAX GYRK%& 5$S^8_P"Q
M_P#M]_'W]A33?C*_[.$_A;POX[^-.D>$O#>K?$S6=#A\3>(?"GAKPI=Z[?KI
MO@_2=4,OARVO-7OM=DGO]7U?3M6DA6RLEL[2*>&.ZCW_ /@J5\3S\8O^"C'[
M97CE+X:C9-\<?$W@_1[I'$D;:-\-X[/X?:=%$R_+LAC\--%A> ZN"2VYC^ZG
M_!%'_@A]\!_VD_@7X/\ VQOVL?[9\?:!XZU'Q"_PU^"=K>7WAWPDV@>'/$&I
M>&E\3>.=3TJYM=;\32:[?:5>WFEZ'9WNEZ18Z<+.6_\ [4NYY8;3ZJ5;+,DX
M5RZ&;4O:X983 TY894O:O$8BI36,5+V4I0C+]Y)U)^UDJ453O44E:G+.TIU)
M<KL[MW[+:Y^ ^L?\%)?^"@OB'Q-_PENH_ML_M+-X@CD61)M-^+/B31=-MRDG
MF(D7AG0[K3_"Z1(W"Q/HKH5 C<.GRU^U_P#P31_X.(_CE\/_ (B^%_A1^W?X
MH@^*OP9\4ZG8:#'\;;W2]/TOX@_"FYO9?LUIK7BR70[.SL?&W@H74T0U^[N-
M.B\3Z':LVJP7NJ6EI+IC?T@_&[_@BS_P3C^,?PJU?X:V7[,GPR^%FHRZ1=6?
MA7XA_"[PW9^$/''@_6&MS'I^NVNLZ1]EN-;DL[A8IKK3_$4FIV&JQB:&^AD,
MS2K_ )LGQ!\$ZG\/O''C_P"&?B1H+C6? 7C+Q?X UR6WQ]FN[_PIKNH^';ZY
M@ )"P7LE@]S%'N)CCF6-F+(2>3+:_#?&&%Q>%CE<,-+#Q@G%X?"4L12A5YXT
MJ^&KX6G3LXSBTX2;2DE&I"I3FV.2J4VGS7OYMKT:?D?Z]=O<07<$%U:SPW-K
M<PQW%M<V\B307$$R+)#/!-&S1RPRQLLD<D;,DB,K*Q4@U^%W_!6#_@MK\-/^
M"?<\GP9^&6@:?\8OVIM1TJVU*3PI=WT]GX)^%FE:I \ND:_\2=1L0;RYO=10
M+=:-X'T>6WUC4K$C4=0U'0M-EL+G4-S]D;]L^[^$7_!"GX6?M?\ Q ,^O:O\
M*/V6KUQ%>F1YO$FO_#^]U7X;^"["=PXFD&OZMH^@6,DX?S62\:8$OR?\]+Q]
MX]\;_%[X@>+_ (F_$;Q"^O\ Q#^)?BO4_%GC+Q/J\\SI>>(O$=^US?W]U*JS
M30Z58-,L-O!;Q2"PT:SM[.RMS';005\CPMPG2QV89A+,?WN"RK%U<&Z<6X1Q
M>*I5*BM)Q:FJ$*=.-6I&,E*<JL*7,HJ;EK4J-1CR[R5_1/\ 6_\ F?>?QH_X
M+)_\%)/C%J]QJGB[]L#Q_P"![2]F;[+X:^%%[IOPC\-VB9/DVME;^%X;+5[K
MR$.Q)=0UG4+V;B2YN)YB9#U'P"_X+:?\%)O@?KFF:YHW[3_B/XO^'[2:,WG@
MOXV-9_$WPOK-I&?WFGRZI.MOXNTQ9>C7NB^)K.^B;YA(XW1/_0=^P7^TA_P;
M]_L/_";P]X7T_P",WPR^(GQ:N-+LI?B7\9?&7P<\=Z_XH\6>)FB,FI'2KC5_
M 5\?#/A:UN99K70O#NC&UM;;38;9KXW^I&YOY_@#_@MK\9O^"1?[3GPQ\.?%
M7]CKQIX"A_:B\-^,=$T[6M,\!_#OQ1X%B^(WPWU5+RUUM?$D-QX3T'P_J&K^
M%;M].UK2M9N9%U=+*/4],\V[AN;>&V^NH8O+L5C(Y7+@W$4<OJ3E0AC:V4TJ
M=!:24:E2#P<*U&C-QLJLL5[2"E"<^6[4,FI)<WM4WO92;?YV;^1_4A_P3$_X
M*7_"W_@I-\%[OQGX;T__ (0;XM> YK#1?C+\)KN^6_NO">M7T$LNG:UH6H&.
M!M=\#^)X[:ZN?#NL&W@N8Y+:^TC5+>#4M.F\WUG]O#]O#X'_ /!/GX(7_P 9
M?C-J%S=W%Y<2:'\//AYH;V[^,?B;XR>UDN+3PYX=M9W6."WB1/M6O^(+S;I/
MAS2P]]?2/*]E97O\-?\ P;Y?&/7?A5_P4[^$OAW3[R>+P]\<?"OC_P"%?C"Q
MC=_)O[>+PQJ/CCPQ-+$#L>;3/%'A:Q,$CC,%M?:B$(,S ^>_\%M?VN=<_:S_
M ."@'Q<_XF5Q-\-_@%K&J? OX6Z4)7_L^VM/"5[]F\;^(X(05C:]\6^-(=2N
M);UHQ<OI&G:)8NYAL8A7SD^":$^*9X&$IPRF.%IYE.*FW5C2J5945@HU'>2Y
ML3"4(U'S3CA[N\JD8R>GM7[._P!J_+\[7O\ =^)WW[3_ /P7Y_X**?M#>(-0
MD\%_$R/]F3P"TTXT;P3\&+>T@UNVLW=A =>^(^M6-YXFUC5/L_EI=3Z6OAW2
MO.#R6.DVF[)^1?!?_!5#_@HSX#UF+6?#G[;7Q]GO8+E;E[+Q/XWD\<Z-<RJ=
MVR^T'QC!KFFW$#'[UN;>.,C(  )K]D?^"&O_  1=^&_[6?@B3]KG]K32]4U[
MX2/XBOM$^#WPEAO[O1]+^(3^&[LV6O\ C?QO?:;-;ZG>^$X=8BO/#^A>&[.[
ML8]6O--U/4M6GFT^.PM;S^I/Q5_P2G_X)Q>,?")\$ZO^QC\ (-#%BVGV\F@_
M#[1O#&N6$1 Q-I_B?P[!I?B.RO58"07T&J)=M("TDS[G#>KC^(.%,DQ$\JI9
M+1Q,:#]CB70PF!E3IS22G3=3%0JU<35A>U5^U24^:'M'-2Y9C"I)<SFU?57;
M_31?UH?R%_$/_@X^_;(^(O[+;?"V.*P^&'[1]EXT\*:A:_M#_"^UTJRT[Q!X
M&TU+]_$>BZWX$\16NMVFB>)=4NCIH.H:%)+HMU9"ZCATW19D7S^I_P""9_[:
M7_!4K]N;X\^+OA5+^V5\3A9>%_A%K?Q!N)+/2O -M*EU:>,O WARP1I4\&L?
M+EA\0ZFQC(PS0JV1Y?/YU_\ !7/]BSX9?L$_MEZ_\"OA%XPUOQ3X'O?!7AOX
MBZ7IWB5DNO$'@./Q7=ZS%%X*U+65VGQ$EG;Z7%J6FZQ<06]]+INHV]K?K<W5
MK)?77[7?\&IGPO%SXP_;'^-D]MC^R]#^%OPETN]*_>;5;KQ!XV\06D;^L2Z?
MX7GG7'2XMCGJ*Z\QH9%@N&,5FV6Y;@HQQ%&&)PDJ^$ISG&KC*U"G%*.(A5G2
MC%QJ6HQFZ=-J;IKDDFU'GE4492>FCL^R?:WW_>?M9^QQ^R)^WO\ "']I_P 5
M?$?X\_M--\1OA+<V?BZV'A]O&7BWQ WC6]UB[5_#VJR^$=8TZUT+P,^B!&NQ
M!I5Y>BV$IT>Q+:>SR+\;?$[_ ()W?\%7?$'Q$\=:UHW[4\6KZ%K7BG7=1T:\
MD^.WQ-\*E]&O]0N+C3+4^&M/\-7>GZ&MC82P6(TVPN9K*V6W"6KM"$->\_ _
M]@__ (**^!OVJ_#/Q/\ B#^US)XJ^&.C>/=0\1>);<^./'-]-XU\,SR7CMH,
MW@*]LH_#6F'5XKB&WFM8[MK#01&TFEM,;:S#9?[6?[!G_!1KXJ_M ?$+Q]\*
MOVI#I7PW\1:C:W7@[PY)\3/'_@L^%-)2QMX3X>70_#VFSZ2$L[N.YF2_MYGE
MU 7/VB[VW+2J/2PF=1H<2U*T.-/#2V,X=P$:V/J<(2_LNE/ XCV=' 4\*L!2
M=+,I0K5,3B,1'DC6H4X4JD5.C1HT^65.]%)X?&^[6G:"Q'OM25W)RYG>":44
MM;-MK1MO\I?C+^Q%^W/^QH?#?C[5/B!:Z3J?Q=^(&C_#6+7?A?\ &'Q/%KVL
M^,/%$ES/I$'BF^O].\+7%S;:C<0W;-JES<Z@EK,))+QK=9EDD_93]D#]C/\
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M\+6Y'.#NN7E<DH3E**K1LXNUTDH_=_FC^C[_ (A2?B?_ -'H^"/_  S>M_\
MS<T?\0I/Q/\ ^CT?!'_AF];_ /FYKY%_9T_X.3/VY?@E\/\ 1_A[X\\(_"O]
MH>+P[8VNEZ/XT\>/XE\.^/I-.LK<6]I!XCU?PY>/IWB:\BC2-9=9NM)MM6OM
MOFZA<W=V\MU+\^_M4?\ !>?_ (*&_M*7>DO9?$G2/V=/"/AO7-%\4:?X5^"$
M%_H<=WK'AW4;?5=*E\7^+-9U"_\ $?B;2(]1M;6:[\-27FF^&]16+R=2TR\C
M?:NU/"^(4L0Z4\QRZG03DEBG2PDXSBK\KC0AA_;\T_=]V2CRW?-)\OO*]&U^
M5M]M?SO8_H!_8 _X-X?%7[''[77PB_:8\6?M,^'/B1I7PKG\5:C%X-TCX;ZG
MX;O-4U36_!NN^&-+F_MBY\5:G%;P:7=:RNIS1&RE-V+46P:(2&1?XP/COINK
M:1\=_CMI.N1S6^MZ=\;?B]9ZK'<AQ<1W\?Q%\2B<S"3+AV8B3#<@,,^E?Z=/
M_!.S]JCQ'^V=^R%\(OC]XQ^&_BGX7>+O%6BFT\4>'O$N@ZCH-IJ.NZ,RV&H^
M*_!0U.&"?5OA_P"*IHSK7A+5T0Q3:=="T,LTUE-*_P#&9_P<'_\ !/[Q9^S9
M^U3XH_:F\*Z!=W/[/W[3&O#Q+J'B"RMVDTWP%\:+^W1?%?ACQ!+&OEZ9#XUN
M+63Q=X8O+GR;6_N[S7-(A=KK3D2;BX5SS&UN(,PP6=UZ;QT\/#!T6HT*<'4P
M&)KU)X>#H6I3E-5JM2FTY2J\CBO>BH)U(+D3@M+W>_5)7UUZ']6__!$3Q;X0
M\6_\$MOV0F\'S69@\-?#N;P;X@L+66.232/&'AOQ#K%CXGT^_2-F,%^VIB74
M9$DQ)+#?P76"EPC-^K%?Y<?[#?\ P4Q_:R_X)[:KK;_ +Q;I%SX*\57\6J>+
MOA/X^TN?Q#\/M>U6*&&V_MJ"SMK[3=4\.>(I+2VMK.XUS0-1LY[VTMK>VU."
M_CM[80?5'[3G_!?G_@HE^TIX2U7P(?&G@OX#^"]=L6TO7K/X':'J>@>)M7M+
MI6@N;-_'NNZWK?B72[74(96M;BW\.S:-<W$<C0F\9)#&?/S+@'-<3FV*K8>O
MA/J6*Q-;$JO6JS56E&O5E5G"=!4Y5*DX2J347"?+42@W*#<DJC6BHI-.Z25D
MM[>9XA_P64^*]G\9?^"F_P"UKXKTW4;;5M)T/QSI?PRTC4+*ZCO;*:Q^&'A?
M1_"5PMI<PLT,L$>N66M+NB9X_-,I5W!S7]8G_!LS\+Y/!?\ P3MU#QW>6@@O
MOC)\=/B-XJ@GP UWH'AL:3X"T=W^16RD_AK50,EAM8%#M//\ -RXL(;J6='B
M%G'<37"2ATE0PJ\LXF$N)1-E7,OF_O3)N,F7+&O]1S_@E5\+&^#/_!.?]CKP
M%*BI=VOP-\'^(]2VJ5WZKX]M7\>:I*P8!@TE_P");ABK<ID1YPHKUN.>7+N&
MLMRRG*\77PF&3M9SIX#"N;E9-I<TW";C=I<UE>UW-+WJDI>3?WL^8_\ @H/^
MQ9^W'^T-\8]%\9_ ']H=?!'P^L_"%AHT'@P^/_'?P^_L+Q#;W=]/J>LLG@ZV
MFMM?76%FL&^TW[F\LS9"TC@^S*COU7[8W[(7[;/Q@^!W[.O@GX4_M(MIOC7X
M::'%8?%O4/\ A)O%7@#_ (6=X@70=+T^+Q0=?\,12ZI/)97MIJ3C3]46*&[&
MJOJ,I6]5HS^N=?B#\)/V)?\ @HGX1_;$T_XO^-?VK8_$GPC@^(NN^(-=T<^-
MO&MVWB7P/?3:C)9^$_\ A7]WI:>%M,)M;BPL%BM[I;31FLQ=Z;-(\$ D\WA[
MB3&8G"X)8C-^$,F?!6#Q&+R2CFG#M"O6SJO6P^*P\\'5J4,)5^N5W3E[D\;*
M+CB*V'Q*<JM.=:GG5HQ4I6IXBI]9DHU'"LTJ:3BU))R7*K[J/V4X[-)_DS\=
M?^">7[=O[,O@OQM^TWXO^)=E*WA>QLW\8>+_  ?\8?&C_$272+^_T_1D:76+
MR'2=4U:TCN;G3XIK%]7D80*C16\@MU0?J+^P_P#L<?M^>#O /QHUGXA_M(7E
MBWQE^!-QH_PPTV_^(?C+XB:AX+\?:[#%?>'_ !M>7FJK<VFBW&C:?-)92OX<
MN[V=WOWE3S7L;>23R_\ ;#_8$_;#_:P^.OQ@U/P#^TY\/?'?PHE\36"VGPVU
M3XG^)(+3X=O:6-L(/!^O^"=!T[6-!LK_ $J]M[J^MY[Q!?7;7/VV>**Z$FWW
M']C7]A']NWX'>%/CKX9\;_M+V=A8>,/A!J'@;X2:9H_BOQ?XUL/ GCB8!='\
M:V:>(=.LAX=AT&U1].@M="#R2177G+#&^G6:M^BY[Q4LRX/H1Q?%W ;SJK/+
M\1BL%_JQ6CB:6"G5R:OALOI0K8*I.A6RVLJV(Q52$(X?$8&E7P^'IQIUH5,7
MR4J')B'RT,5[-<RC+VRLY)5%*;:DDU-645NI-2;NFH_DQXS_ &*_^"@C_'GP
M_P#LC^+?C)J_BKQ)\1? >K^/+9]4^.OC[5_AYJW@[1+Q[+69M:M=8G>[EDAU
M&..$:/<:#<FY::&>(&W2>2#ZJ^$?_!+3_@I7\/\ Q5\/QI?[1>F^ _"?A;Q'
MHEYY.@?&#XCWVD:+HUCJ<-[J%OIW@D6%MH-]%<VR7,"Z/-#!IUS)=,+DQQ/*
MXXJ\_P""0/\ P45O?%$'CW4_CEX*O_'5E"8;?QS=_%_XFR^*K:W595:*U\12
M^'O[6L[-TFG#6L-U%;[)YE:(B23=^E>L_LY?M>?$W_@G[\/OA%\//VOM#\1?
M''PYXI>?Q=\4?#WCG6+C2?%.B6.L:X[_  ^D^(NA07?B-Y_#MK?:/9S7\]LE
MSJ%QH8M=2CBAD5Z[\^XRE##Y1A<LXP\/,3A\9/#Y;G=2/"E2KA<'BL31S"-;
M.I4W@YX>CA/8JAAH4)0^M*I[T)5:,JU/#12P]W4<\/BXN*<Z:]NE*23A:G?F
M3<KWDVG:W9I.6+_P4 _8H_;C_:%^,^C^,_@+^T:O@?X>VOA'3-&@\(/X_P#'
MW@#^P-?M;F[DU76/(\%VTUKKB:P);.<W5XYOK=K0V20"VAMVD_6/X6:!XN\*
M?#7P#X9\?>*O^$X\;^'_  ?X>T;Q;XR^SFT/BCQ#INE6MIJVNF!OG0ZG>Q37
M9,F)7,IDE D9@/D__@G[\"?VCO@!\(-:\)?M*_%S_A:_BJ_\8WVL:#(-=USQ
M4GA;P[+8V-M'HR>)/$EM::M?BYOK>[U0VKP_9-.-V8K61S),%^[*_"N)<XQ%
M2CA.&5B\DS/*^'*E6AEV:Y3E5'!3Q].5.,76JXJ5"CC<5%^TE%_6?BJTI5FZ
MDN2J_3HTTG*MRU(3K).<*DW+E=]E&[C';IT=M-49VL:K9Z%I&JZWJ,JP:?HV
MFWVJWT[L%2&ST^UEN[J5F8A56."%W9B0  23@5_D6_%;QW/\1_B9\5?BA>3S
M7EQ\0/B-\0OB!+<7!9IYD\5^+-9\10>87^<F.TOH(%#_ #+'$B'[M?Z??_!3
M;XKGX(_\$^_VP/B5'N^U:'\!?']CINQ@DIU?Q3HTWA+1Q"Q(_?'5-=M/*Y!,
MFW!'4?Y=7@CP9>^.?%/@CX<:;YCZCXW\4^$_ 5BT*;Y?M?BK6].\.0RQI@[G
MCDU 3!2"&*;2#FOJO#:@H8?-\=/2+JX?#\SMI"C2JXFJ^]H\\6]4M%UV*[UB
MO5_?9(_T-?V3O^"97[*7QF_X)>?L8_"K]JCX->#?&&I:1\"_"VNVWBFZC?PY
MXZ\,ZE\0TN/']XNA^.='GTWQ-I3F\\3223V$>J&PGG4B[L[@)MKYROO^#8G_
M ()XZKKRSZ+\5_VD]-TN21IIO#=C\2_!>I.(]Q=H;+4KWP%=:E;P1H0B-.;V
M95 :2:1B2?WT\0? ;X5>-?A?X:^$'CWP9HGC+P'X8L/#%EI_A[6[=KG3HW\)
M6$.GZ+<"(/&?-LH8@(26XR<@YKX4_P"":7P'^#FB?#:]^*VC_#OPYIWQ%LOB
MS^T3X0M?%\$%PVM0>&-,^+_B_0M.T2.ZGN92NGV.BZ=I^EVT(&([.RMX\EE9
MV^?PF9XO^S,[S:CGN<8.M2S"%L#0HX>K@YSS:OF%3#256OB93H*+P]7ZQ[+"
MIQO2=)5).IRN2]^G#D@XN+;DW)27(HWT4;/=6N^][:'6?L@?\$JOV$/V(+Q/
M&/P2^$6ER>/([=K<?%OX@ZM/X^\>V\++Y$ZZ3XAUYYK7PPMP#)%=CPG8Z$ET
MLLL%PLD3>4/T6N+ZRM-GVJ\M;;S 3']HN(8=X'4IYCKN R,E<XS7\X<OQ"_:
M-B_X)8>*O"EO\ -,G^$/_"/?$"W/QH/QMT>+65TB3XSZ_<W&LCX>OH+:V9[:
M]>73DTL:Z)Y1$LZ2K$ZPC[)_;?\ "=UXW_:4_8_\/6OP.\/?M%M+\*_CQ>M\
M,/%?C*T\#:'=BSC^&"CQ#+K>H66HV9O-$:<"UM)+.26X6_N#$\;1%J[\9PAB
MJN:.GFF>QQ,I8SB/#/%+%8'%5%0X>R_#XY3K3JYC'"X"KB?K'LGA,96PRP7*
MYU+\UC-8E<EX4VO=HRLU.*O5FXV5H-R4;7YHI\VR/U9\0Z7X0\8^&M8T+Q5I
M_AWQ1X0URRN=)U[2->MM-UGP[JVG7:&&[T[5;&_2XTZ^M+A',4]K=Q212*VQ
MT(.*_"'XQ_\ !MY_P3>^+>N77BKP-:_%3X&G4)9YY=$^$?CVW?P,9Y9&::2Q
M\.^+]'\6Q:4J2;EBLM$O]-TJV7=%#IZ*%">_?M/^ U\$_P#!.77_  V/V?O#
M'P3NM0^*7PLFU#X*^%?&EEXCT*\GU3XZ>![-K*3Q?966FV1'C*R2W@U"=K1(
M=/COGCN1*MO(7Z+]@7P\FB_'']JV_P!-^'VC?LS^%O"*> O 7B#]FRR\:7/B
MI=*\8Z;9ZKXHN/C/=2M#:>'--T?QOX;UW3=+T"^\.(;+6K'P[=W.I.E_8R(O
M/A,JQ.6Y-FN=Y9GV*POU3&8O#1H4G@IT\7#"XG*L)3<_JN.Q:J5,14S-JCB,
M+A,7E]+ZNX5L?1EBL,JK=7FJ0IRII\T8MOWDXN49R?Q1C914-5)QF[W47:5O
M+/V;/^#?_P#X)P?LZ^)=-\7S^ /$WQU\8:)=6NIZ7>?'GQ-#XUT;2K^!]]O>
MVW@:PTS0?!MP4FB,EM_;NA:R8)$+PR+(NX5?B)_P0 _X)D_$GQWXU\;^-/!W
MQ'NO&'Q(\3Z_XM\221?&[QKIQO=<\5ZC=:GJ<MEIUMJ<,-E;R75U*ME964,=
MM:0+%;VL<<4**OG7P&_:Q\)ZI^VMI?QT7Q]JE[:_M1_$;QK\ -2\"W6D^*X-
M%\'?#OPBT5C^S/XMM;^^TBV\+K>^+-=T3Q'-JLUAJ]P9_P#A9VFPJ+B2U8IW
MW[2OPKU+XN_MM?'_ ,.:5^S5X>_:'U8?L[_!^VT/4?$_Q,MOAO9?"C5M4OOB
M);V7B:UO7BN-7N'N+M(+N=_#40U>W&C1&%Q++"R^O/).(<+F_L<SXCS/!.>0
M1S2MC)RAA73G0Q>"PF-P'_"AB\%A(T\!CL:E*NJE*&*5)U,/3J5*E&#CV\)4
M[PIQE:KR*-W*Z<92C/W(RE><8Z*SLW9NR;/V*\ >"_!GP<^'O@;X9>$XH-!\
M&?#_ ,*:!X)\)V%W>[WM=!\+Z5::/I5M)=W<GG7D\5C:0">YF=Y[B7?/,S22
M,Q^)?VL/^"7W[!/[;=U<>*_C;\&?#%_XW:-;:3XK>!]3N? OC]MH2*)-4\4^
M%KJQ;Q 8D\J*WA\4Q:U%#&L44,21JB5\X?M0?"GQU81_\$V?A'XT\$Z-^UMX
MZ\/Z?\2="\6^&O%?BQ/!FB_$;7/#?P4MEU3Q!?\ B+5;6]17TVYM9=<LY-1L
MYKK4KBUB\Y4N[AV'2?'GP&/AO_P3G^,5H?@#X7_9CO+CQY\/-:U3P)X+\:V?
MC/3/)A^,?POA/BB?Q'I=CI4 EO\ 3K,?;+;[,ALK:SQ/(Z%FKQL+D'LIY+B<
M'Q!5CC<[S1X.EB,)/"T_W-3.\?E?UU4)YA2SBO3KK"K&Q<\ L-+ZS"C6J1JQ
MDRW6?[Q.DN6G#F:ES;^SC/EYE%TTUS<K]^_NMI-'QG<?\&O/_!/PZS!+%\3_
M -J.VTN0L_\ 8;?$?P7+<3E"KR+#J<OPX^V+"BG:RB.21$8%IBV&K]3_ -C[
M_@GA^P]^PI#?S_L]?#7PSX?\6:I;FQUOXC^)-:?Q?\2-3M0%$FGS>+_$%U=Z
MCIVFR/&))]%T0Z5I$LRB62P,B*RW?CI<B3]N3]@FWM[DN3I'[5%Y/;P3D[K,
M?#?PU#'>3P1OAK47,T,,5Q*AB%Q*B1OYC 5\V^+?V/?V8/\ AO?X:> C\$O
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LC:5WLON6]E;LZ***XR@HHHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !% 4X# 2(  A$! Q$!_\0
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M[Q=XGUWQM8V5WK$\MMAY)4*KAE53QP/7%>B^/?'4/@VPB6.);C4;G/D1,<*
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M_*WH/ZGM7AOPGU"2Q\?VD2L1'=H\,@]>"P_457^).OR:]XSO/G)MK-C;0+V
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MK1L&>V>(["2Q^ T%JH(,=M;LX'NRL?YUXQI5DNI:O9V+W"VZW,JQ><PR$R<
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M +[J?6;%]0\6:A$FE1W[_9(@K23>6(22W/K^7I5\DU+5]!7.QM;:#3[*"TA
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M6ZDWI<     & *BNK6WO;:2VNH8YH)!M>.10RL/<&I:*@#SV_P#@UX7NYS+
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1%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
